[COMPANY_001] Research and Development
AIN457
Clinical Trial Protocol CAIN457M2301
A randomized, double- blind, multicenter study assessing 
short (16 w eeks) and long -term efficac y (up to 1 year), 
safety , and tolerability  of 2 subcutaneous secukinumab 
dose regimens in adult patients w ith moderate to severe 
hidradenitis suppurativ a (SUNSHINE)
Document type: Amended Protocol Version
EUDRACT number: 2018 -002063 -26
Version number: 02 (Clean )
Clinical trial phase: III
Release date: 08Jan 2021
Property of [COMPANY_001]
Confidential
May not be used, divulged, published, or otherwise disclosed
without the consent of [COMPANY_001]
Clinical Trial Protocol Template version 1.0 dated 01 -Dec-2017

[COMPANY_001] Confidentia l Page 2
Amended Protocol Version 02 ( Clean ) Protocol No. CAIN457M2301
Table of con tents
Table of contents ................................ ................................ ................................ ................. [ADDRESS_37279] of abbreviations ................................ ................................ ................................ ............ 7
Glossary  of terms ................................ ................................ ................................ ............... 10
Amendment 2 (08 -Jan-2021) ................................ ................................ ............................. 12
Amendment 1 (17 -Jun-2020) ................................ ................................ ............................ 13
Protocol summary ................................ ................................ ................................ .............. 16
1Introduction ................................ ................................ ................................ ....................... 19
1.1 Background ................................ ................................ ................................ ............ 19
1.2 Purpose ................................ ................................ ................................ .................. 21
2Objectives and endpoints ................................ ................................ ................................ ...21
3Study  design ................................ ................................ ................................ ...................... 24
4Rationale ................................ ................................ ................................ ............................ 27
4.1 Rationale for stud y design ................................ ................................ ..................... 27
4.2 Rationale for dose/regimen and duration of treatment ................................ .......... 29
4.3 Rationale for choice of control drug s (comparator/placebo) ................................ .30
4.4 Purpose and timing of interim anal yses/design adaptations ................................ ..31
4.5 Risks and benefits ................................ ................................ ................................ ..31
5Population ................................ ................................ ................................ .......................... 32
5.1 Inclusio n criteria ................................ ................................ ................................ ....33
5.2 Exclusion criteria ................................ ................................ ................................ ...33
6Treatment ................................ ................................ ................................ ........................... 35
6.1 Study  treatment ................................ ................................ ................................ ......35
6.1.1 Investigational and control drugs ................................ .......................... 35
6.1.2 Additional study  treatments ................................ ................................ ..35
6.1.3 Treatment arms/group ................................ ................................ ........... 36
6.1.4 Treatment duration ................................ ................................ ................ 36
6.2 Other treatment(s) ................................ ................................ ................................ ..[ADDRESS_37280] numbering ................................ ................................ ................ 39
6.3.2 Treatment assignment, randomization ................................ .................. 40

[COMPANY_001] Confidentia l Page 3
Amended Protocol Version 02 ( Clean ) Protocol No. CAIN457M2301
6.[ADDRESS_37281] demographics/other baseline ch aracteristics ................................ ............. 52
8.2.1 Demograph y................................ ................................ .......................... 52
8.2.2 HS medical history /diagnosis ................................ ................................ 52
8.2.3 Prior HS medications and therap y................................ ......................... 52
8.2.4 Hurley  stage ................................ ................................ .......................... 52
8.2.5 Smoking History ................................ ................................ ................... 53
8.2.6 Relevant medical history/current medical conditions........................... 53
8.2.7 Prior and concomitant medications................................ ....................... 53
8.2.8 Determination of the tuberculosis status................................ ............... 53
8.3 Efficacy ................................ ................................ ................................ .................. 56
8.3.1 Hidradenitis Suppurativa Clinical Response (HiSCR) ......................... 56
8.3.2 Patient's Global Assessment of Skin Pain -NRS in the past 24 
hours ................................ ................................ ................................ ......57
8.3.3 Modified Hidradenitis Suppurativa Score (mHSS)............................... 57
8.3.4 HS-Physician’s Global Assessment (HS -PGA) ................................ ....58
8.3.5 Dermatology  life qualit y index (DL QI) ................................ ................ 58
8.3.6 Health Status Questionnaire (EQ -5D-3L)................................ ............. 59
8.3.7 Hidradenitis Suppurativa Sy mptom Diary ................................ ............ 59
8.3.8 Patient Global I mpression of severit y (PGI -s)................................ ......60
8.3.9 Patient Global I mpression of Change (PGI -c)................................ ......60
8.3.10 Work Productivity  and Activity  Impairment Questionnaire: 
Specific Health Problem (WPAI -SHP) ................................ ................. 60

[COMPANY_001] Confidentia l Page 4
Amended Protocol Version 02 ( Clean ) Protocol No. CAIN457M2301
8.3.11 Patient's lesion count ................................ ................................ ............. 60
8.3.12 Appropriateness of efficacy  assessments ................................ .............. 60
8.4 Safety ................................ ................................ ................................ ..................... 61
8.4.1 Physical examination ................................ ................................ ............ 61
8.4.2 Vital signs ................................ ................................ .............................. 62
8.4.3 Height and weight ................................ ................................ ................. 62
8.4.4 Laboratory  evaluations ................................ ................................ .......... 62
8.4.5 Pregnancy  and assessments of fertility ................................ ................. 64
8.4.6 Appropriateness of safety  measurements ................................ .............. 64
8.5 Additional assessments................................ ................................ .......................... 65
8.5.1 Clinical Outcome Assessments (COAs) ................................ ............... [ADDRESS_37282] -study  treatment ................................ .......................... 70
10Safety  monitoring and reporting ................................ ................................ ........................ 71
10.1 Definition of adverse events and reporting requirements ................................ ......71
10.1.1 Adverse events ................................ ................................ ...................... 71
10.1.2 Serious adverse events ................................ ................................ .......... 73
10.1.3 SAE reporting........................................................................................ 74
10.1.4 Pregnancy  reporting ................................ ................................ .............. 74
10.1.5 Reporting of stud y treatment errors including misuse/abuse ................ 75
10.2 Additional Safety  Monitorin g................................ ................................ ................ 75
10.2.1 Data Monitoring Committee ................................ ................................ .75
10.2.2 Steering Committee ................................ ................................ ............... 76
11Data Collection and Database management ................................ ................................ ......76
11.1 Data collection................................ ................................ ................................ .......76
11.2 Database management and quality  control ................................ ............................ 76
11.3 Site monitoring ................................ ................................ ................................ ......77
12Data analy sis and statistical methods ................................ ................................ ................ 78

[COMPANY_001] Confidentia l Page 5
Amended Protocol Version 02 ( Clean ) Protocol No. CAIN457M2301
12.[ADDRESS_37283] demographics and other baseline characteristics................................ ......78
12.3 Treatments ................................ ................................ ................................ ............. 79
12.4 Analy sis of the primary  endpoint(s) ................................ ................................ ......79
12.4.1 Definition of primary  endpoint(s) ................................ ......................... 79
12.4.2 Statistical model, hy pothesis, and method of anal ysis.......................... 80
12.4.3 Handling of missing values/censoring/discontinuations ....................... 80
12.4.4 Sensitivity  and Supportive anal yses................................ ...................... 81
12.5 Analy sis of secondary  endpoints ................................ ................................ ........... 82
12.5.1 Efficacy  and/or Pharmacody namic endpoint(s) ................................ ....82
12.5.2 Safety  endpoints ................................ ................................ .................... 85
12.5.3 Pharmacokinetics ................................ ................................ .................. 86
12.5.4 DNA ................................ ................................ ................................ ......86
12.5.5 Biomarkers ................................ ................................ ............................ 86
12.5.6 PK/PD relationships ................................ ................................ .............. 86
12.5.7 Patient reported outcomes ................................ ................................ .....86
12.6 Analy sis of exploratory  endpoints ................................ ................................ ......... 86
12.7 Interim anal yses................................ ................................ ................................ .....89
12.8 Sample size calculation................................ ................................ .......................... 89
12.8.1 Primary  endpoint(s) ................................ ................................ ............... 90
12.8.2 Secondary  endpoint(s) ................................ ................................ ........... 90
13Ethical considerations and administrative procedures ................................ ...................... 91
13.1 Regulatory and ethical compliance ................................ ................................ ........ 91
13.2 Responsibilities of the investigator and IRB/ IEC................................ .................. 91
13.3 Publication of study  protocol and results ................................ ............................... 91
13.4 Quality  Control and Quality  Assurance ................................ ................................ .91
14Protocol adherence ................................ ................................ ................................ ............ 92
14.1 Protocol Amendments ................................ ................................ ........................... 92
15References ................................ ................................ ................................ ......................... 93
16Appendices ................................ ................................ ................................ ........................ 96
16.1 Appendix 1: Clinically  notable laboratory  values and vital signs ......................... 96
16.2 Appendix 2: Blood samples collection................................ ................................ ..97
16.3 Appendix 3: Ty pe I alpha for the pain hy pothesis ................................ ................. [ADDRESS_37284] of tables
Table 2-1 Objectives and related endpoints ................................ .......................... 21
Table 6-1 Investigational and control drug................................ ............................ 35

[COMPANY_001] Confidentia l Page 6
Amended Protocol Version 02 ( Clean ) Protocol No. CAIN457M2301
Table 6-2 Prohibited medication ................................ ................................ ........... 38
Table 8-1 Assessment Schedule ................................ ................................ ............ 48
Table 8-2 Hurley  stages ................................ ................................ ......................... 52
Table 8-3 Modified Hidradenitis Suppurativa Score (mHSS)............................... 57
Table 8-4 Hidradenitis Suppurativa Phy sician's Global Assessment Scale 
(HS-PGA) ................................ ................................ .............................. 58
Table 10-1 Guidance for capturing the study  treatment errors including 
misuse/abuse ................................ ................................ ......................... 75
Table 16-1 Blood log: Time schedule for blood sampling...................................... [ADDRESS_37285] of figures
Figure 3 -1 Study  design ................................ ................................ .......................... 26
Figure 3 -2 Study  design in case of global health disruptive event ......................... 27
Figure 4 -1 Predicted s ystemic exposure with 2 and 4 weeks dosing intervals 
during maintenance at the 300 mg dose level ................................ .......30
Figure 8 -1 Tuberculosis screening flowchart ................................ ......................... 55
Figure 12 -1 Testing strategy ................................ ................................ ..................... 84

[COMPANY_001] Confidentia l Page 7
Amended Protocol Version 02 ( Clean ) Protocol No. CAIN457M2301
List of abbreviations
A abscess
AE adverse event
ALT alanine aminotransferase
ALP alkaline phosphatase
AN abscesses and inflammatory nodules
ANCOVA analysis of covariance
AST aspartate aminotransferase
BD-2 beta-defensin -2
CDS core data sheet
CFR Code of Federal Regulation
COAs clinical outcome assessments
COVID -19 Corona Virus Disease 2019
CRP (hsCRP) (high sensitivity) C -reactive protein
CSR clinical study report
CTC Common Toxicity Criteria
CTT clinical trial team
CV coefficient of variation
DF draining fistulae
DLQI Dermatology Life Quality Index
DMC Data Monitoring Committee
DNA deoxyribonucleic acid
eCRF electronic case report/record form
EDC electronic data capture
ELISA enzyme -linked immunosorbent assay
EMA European Medicines Agency
EOT end of treatment
EPAR European public assessment report
EQ-5D Euro -QoL (EQ -5D-3L) -standardized tool to assess quality of life in 3 levels
ESR erythrocyte sedimentation rate
EU European Union
F fistulae
FAS full analysis set
FDA Food and Drug Administration
FSH follicle -stimulating hormone
GCP Good Clinical Practice
GGT gamma glutamyl transferase
HbA1c hemoglobin A1c
HDL high density lipoprotein
HiSCR Hidradenitis Suppurativa Clinical Response
HIV human immunodeficiency virus
HRQoL health -related quality of life
HS hidradenitis suppurativa
HS-PGA Hidradenitis Suppurativa Physician's Global Assessment
i.v. intravenous
IB Investigator’s Brochure
ICF informed consent form

[COMPANY_001] Confidentia l Page 8
Amended Protocol Version 02 ( Clean ) Protocol No. CAIN457M2301
ICH International Council for Harmonisation of Technical Requirements for Pharmaceuticals for 
Human Use
IEC independent ethics committee
IFU instructions for use
IG immunogenicity
IgG1 immunoglobulin G1
IL-17A interleukin -17A
IRB institutional review board
IRT interactive response technology
LDL low density lipoprotein
LLN lower limit of normal
LLOQ lower limit of quantification
MedDRA Medical Dictionary for Regulatory Activities
mHSS modified Hidradenitis Suppurativa Score
MHRA Medicines and Healthcare products Regulatory Agency
MMRM mixed model repeated measures
mRNA messenger RNA
N inflammatory nodules
NRS Numerical Rating Scale
PD pharmacodynamic(s)
PFS pre-filled syringe
PGI-c Patient Global Impression of change
PGI-s Patient Global Impression of severity
PK pharmacokinetic(s)
[COMPANY_003] purified protein derivative
PRO patient reported outcome
PSUR Periodic Safety Update Report
PTY patient -treatment years
q2w once every two weeks
q4w once every four weeks
QFT QuantiFERON®TB-Gold In -Tube assay
QoL quality of life
RAS randomized analysis set
RNA ribonucleic acid
s.c. subcutaneous
SAE serious adverse event
SC steering committee
SD standard deviation
SGOT serum glutamic oxaloacetic transaminase
SGPT serum glutamic pyruvic transaminase
S[LOCATION_003]R suspected unexpected serious adverse reactions
TB tuberculosis
TNF-α tumor necrosis factor -α
ULN upper limit of normal
US [LOCATION_002]
VAS visual analog scale
WBC white blood cell(s)

[COMPANY_001] Confidentia l Page 9
Amended Protocol Version 02 ( Clean ) Protocol No. CAIN457M2301
WHO World Health Organization
WPAI-SHP Work Productivity and Activity Impairment Questionnaire: Specific Health Problem
β-hCG β-human chorionic gonadotropin

[COMPANY_001] Confidentia l Page 10
Amended Protocol Version 02 ( Clean ) Protocol No. CAIN457M2301
Glossary  of terms
Assessment A procedure used to generate data required by [CONTACT_37214] A specific group of subjects fulfilling certain criteria
Control drug A study drug used as a comparator to reduce assessment bias, preserve blinding of 
investigational drug, assess internal study validity, and/or evaluate comparative eff ects of 
the investigational drug.
Dosage Dose of the study treatment given to the subject in a time unit (e.g. 100 mg once a day, 75 
mg twice a day)
Enrollment Point/time of subject entry into the study at which informed consent must be obtained (i.e. 
prior to starting any of the procedures described in the protocol)
Epoch Interval of time in the planned conduct of a study. An epoch is associated with a purpose 
(e.g. screening, randomization, treatment, follow -up), which applies across all arms of a 
study.
Estimand A structured framework that translate the trial objective into a precise definition of the 
treatment effect that is to be estimated
Healthy volunteer A person with no known significant health problems who volunteers to be a study 
participant 
Intercurrent 
eventsEvents occurring after treatment initiation that affect either the interpretation or the 
existence of the measurements associated with the clinical question of interest.
Investigational 
drugThe study drug whose properties are being tested in the study; this definition is consistent 
with US CFR 21 Section 312.3 and is synonymous with “investigational new drug” or 
“investigational medicinal product”.
Investigational 
treatmentAll investigational drug(s) whose properties are being tested in the study as well as their 
associated treatment controls. This includes any placebos, any active controls, as well as 
approved drugs used outside of their indication/approved dosage or tested in a fixed 
combination. Investigational treatment gene rally does not include other treatments 
administered as concomitant background therapy required or allowed by [CONTACT_37215]/dosage.
Part A single component of a study which contains different objectives or populations within 
that single study. Common parts within a study are: a single dose part and a multiple dose 
part, or a part in patients with established disease and in those with newly -diagnosed 
disease.
Patient An individual with the condition of interest
Period A minor subdivision of the study timeline; divides phases into smaller functional segments 
such as screening, baseline, titration, washout, etc.
Premature 
subject 
withdrawalPoint/time when the subject exits from the study prior to the planned completion of all 
study drug administration and assessments; at this time all study drug administration is 
discontinued and no further assessments are planned.
Randomization 
numberA unique identifier assigned to each randomized subject, corresponding to a specific 
treatment arm assignment
Screen Failure A subject who is screened but is not treated or randomized
Stage A major subdivision of the study timeline; begins and ends with major study milestones 
such as enrollment, randomization, completion of treatment, etc.
Study completion Point/time at which the subject came in for a final evaluation visit or when study drug was 
discontinued whichever is later.
Study drug 
discontinuationPoint/time when subject permanently stops taking study drug for any reason; may or may 
not also be the point/time of premature subject withdrawal.
Study 
drug/treatmentAny drug (or combination of drugs) administered to the subject as part of the required 
study procedures; includes investigational drug, active drug run -ins or backgrou nd 
therapy.
Subject An individual who has consented to participate in this study. The term Subject may be 
used to describe either a healthy volunteer or a patient.

[COMPANY_001] Confidentia l Page 11
Amended Protocol Version 02 ( Clean ) Protocol No. CAIN457M2301
Subject number A unique number assigned to each subject upon signing the informed consent. This 
number is the definitive, unique identifier for the subject and should be used to identify the 
subject throughout the study for all data collected, sample labels, etc.
Variable Information used in the data analysis; derived directly or indirectly from data collected 
using specified assessments at specified time points .
Withdrawal of 
consent ( WoC)Withdrawal of consent from the study occurs only when a subject does not want to 
participate in the study any longer, anddoes not allow any further collection of personal 
data.

[COMPANY_001] Confidentia l Page 12
Amended Protocol Version 02 ( Clean ) Protocol No. CAIN457M2301
Amendment 2 (08-Jan -2021 )
Amendment Rationale
The purpose of thisamendment is to update the statistical analy sis section including adjust ing
the split of the overall alpha level allocat ing80to testing the high dose secukinumab regimen 
(300 mg q2w) versus placebo , revising the definition of the baseline for assessments and adding 
additional anal yses as described below .
This change has been deemed necessary  following the recentl y available results from study 
CAIN457A2324, conducted in patients affected by [CONTACT_37216] ≥90kg and treated with secukinumab 300 mg every  four weeks (q4w) or every  two 
weeks (q2w ). The study  CAIN457A2324 showed that in psoriasis patients who weigh ≥90kg, 
secukinumab [ADDRESS_37286], without altering the well 
characterized safet y profile of secukinumab. Patients with Hidradenitis Suppurativa (HS) are 
generall y heavier than patients with psoriasis ( Storer et al 2018 ), and it seems reasonable to 
assume that the same weight -based response seen in psoriasis could apply  to HS patients as 
well. These new findings, paired with the absence of safet y concerns noted by [CONTACT_37217] (DMC) when evaluating the 300 mg q2w data from the 
CAIN457M2301 and CAIN457M2302 studies (17-Jun-2020), and the safet y profile seen in 
study  CAIN457A2324, support the revi sion of the statistical analy sis section.
In addition, this amendment introduces the value of the individual lesion count assessed at the 
baseline visit only to be used as ‘baseline’ in the statistical analy ses, instead of the weighted 
average across the two screening visits and the baseline (randomization) visit. This change 
follows the guidance from the FDA advice letter on studies CAIN457M2301 and 
CAIN457M2302 dated 20-Aug-2019 stating: “As the treatment will be initiated at baseline and 
not at screening visits, for interpretation of study  findings, we recommend that you use the 
assessments collected at the time of the baseline visit” and also guidance from theFDA advice 
letter on studies CAIN457M2301/M2302 dated 10-Nov-2020 “For interpretation of study
findings, wemaintain our recommendation that you use the assessments collected at 
therandomization visit as the baseline value”. The weighted average value will still be 
considered in sensitivity  anal yses.
In order to take into account the variability  and the subjectivity  of the Hidradenitis Suppurativa 
Clinical Response (HiSCR), the inter-rater variability  when evaluating the draining fistulae and 
their longevit y often requiring surgical excision (Revuz J 2009 ), a secondary  endpoint 
evaluating only the abscesses and inflammatory  nodules (AN) count has been added. Anal yzing 
AN count on the original, continuous scale, enables a more sensitive and granular approach to 
summarizing the clinical effect of treatment ( Kimball et al 2018 ).
Moreover, based on the evidence that biologic -naive (bio- naive) patients respond better to 
biologic 
therapi[INVESTIGATOR_014], including secukinumab, compared to those who are bio-experienced 
(Garcia -Montoy a and Marzo -Ortega 2018 ), and considering that it is plausible to assume a dose-
response influenced b y weight, the exploratory  objective section has been updated to include a 
specific analysis to evaluate the benefit of secukinumab in the bio-naive population and in the 
patients with body  weight above and below 90 kg. Furthermore, anexploratory  objective related 

[COMPANY_001] Confidentia l Page 13
Amended Protocol Version 02 ( Clean ) Protocol No. CAIN457M2301
to C-reactive protein (CRP )and erythrocy te sedimentation rate (ESR)has been added to explore
treatment effect with regard to inflammatory  marker s.
Lastl y, as introduced in the previous Amendment 01, the number of patients to be randomized 
has been formally  increased to account for the disruptive impact of the COVID- 19 pandemic.
Changes to specifi c sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions.
The major changes made to the protocol are listed below.
Section [ADDRESS_37287] been updated with the addition of the reduction of AN count 
as secondary  and exploratory  endpoints, evaluation of inflammatory  markers (ES R and 
CRP) and of the achievement of HiSCR in bio -naive patients, and in patients with body  
weight lower and higher than 90 kg (90 kg and ≥90 kg) as exploratory  subgroup 
analyses.
Section [ADDRESS_37288] been updated with the increase of the target 
population (approximately  541patients). 
Section 4.2 Rationale for dose/regimen and duration of treatment and Section 4.[ADDRESS_37289] 
been updated including the available data from the recent CAIN457A2324 study .
Section 12.4.1 has been edited with updated baseline definition. 
Section 12.4.4 has been updated with additional sensitivity  analy sis for baseline and 
weighted baseline values.
Section 12.5.[ADDRESS_37290] the updated alpha 
allocation.
Section 12.6 has been updated with the pre -specified subgroup anal yses.
Section 12.8 , Section 12.8.1 Primary  endpoint(s) and Section 12.8.[ADDRESS_37291] been updated 
with power calculations.
This protocol amendment also includes corrections of minor errors across sections of the 
protocol.
IRBs/IECs 
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (IECs) and Health Authorit ies. The changes described 
in this amended protocol require IRB/IEC and Health Authorit y approval according to local 
regulations prior to implementation. The changes herein affect the Informed Consent. Sites are 
required to update and submit for approval a revised Informed Consent that takes into account 
the changes described in this protocol amendment.
Amendment 1 (17-Jun -2020)
Amendment rationale 
The rationale for the amendment reflects the guidance released from several Health Authorities 
(FDA, EMA, MHRA) to introduce a level of flexibility  in drug dispensation, protocol 

[COMPANY_001] Confidentia l Page 14
Amended Protocol Version 02 ( Clean ) Protocol No. CAIN457M2301
assessment sand visit schedule if a major health care event requires it (i.e. COVI D-19 
pandemic).
While adherence to protocol procedure and GCPs remains mandatory , [COMPANY_001] has edited the 
wording in some sections of the protocol to allow the patients in thetrial to continue treatment 
while being monitored for safety in these situations. 
These changes will reduce the risk of exposure for patients and site staff, and potentially  the 
risk for transmission of infectious diseases (e.g. COVID -19). 
In addition, a ‘special scenario’ has been added to the study  design to ensure a careful 
assessment of lesion count at Week 52, by [CONTACT_37218] 3 
unscheduled visi ts. 
In case of a global health crisis impeding the patients (or the sites) to attend (or perform) 
Week 52 study  visit on site, the patients in the study will be allowed to receive additional study 
treatm ent up to 12 weeks after Week 50 , or until they can return to the study site to perform the 
Week 52 assessment (whichever occurs first). 
This additional, optional phase will permit the patients to be assessed for eligibility to roll over 
in the 4 years, long-term extension study . During this period, the patients will continue to be 
monitored for safety .
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions.
The major changes made to the protocol are listed below.
Section [ADDRESS_37292] been edited with the option of performing up to 3 
unscheduled visits if, in case of pandemic/epi[INVESTIGATOR_37182], the patient cannot be 
assessed on site for the Week 52 lesion count.
Section [ADDRESS_37293] been modified to allow the 
recruitment of additional patients if missing data due to a global health event jeopardize 
the power of the predefined statistical tests. The number of patients that may be included 
to compensate the missing data is not expected to exceed 15% of the pre- planned 
population.
Section [ADDRESS_37294] safety  information, remote site initiation visits or 
monitoring related activities in case of pandemic/epi[INVESTIGATOR_37183]. 
Section 5.[ADDRESS_37295] been edited adding clarity  on the p rocess to assess the 
eligibility  of patients with latent TB at screening.
Section 7 has been edited include the possibility for patients to provide their consent 
remotely , if appropriate.
Sectio n 8.3 .7has been edited to clarify  the mandatory  completion of the HS Patients’ 
Diary  in countries where available.
This protocol amendment also includes corrections of minor errors or inconsistencies across 
sections of the protocol and increase clarit y ofthe text.

[COMPANY_001] Confidentia l Page 15
Amended Protocol Version 02 ( Clean ) Protocol No. CAIN457M2301
IRBs/IECs 
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (IECs) and Health Authorities. The changes described 
in this amended protocol require IRB/IEC and Health Authorit y approval according to local 
regulations prior to implementation.
The changes herein affect the Informed Consent. Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes described in this 
protocol amendment.

[COMPANY_001] Confidentia l Page 16
Amended Protocol Version 02 ( Clean ) Protocol No. CAIN457M2301
Protocol summary
Protocol number CAIN457M2301
Full Title A randomized, double -blind, multicenter study assessing short (16 weeks) and long -term 
efficacy (up to 1 year), safety, and tolerability of 2 subcutaneous secukinumab dose 
regimens in adult patients with moderate to severe hidradenitis suppurativa
Brief title Study of efficacy and safety of two secukinumab dose regimens in subjects with 
moderate to severe hidradenitis suppurativa
Sponsor and 
Clinical Phase[COMPANY_001]/Phase III
Investigation 
typeDrug
Study  type Interventional
Purpose and 
rationaleThe purpose of this study is to demonstrate superiority of secukinumab at W eek 16, 
based on HiSCR rates versus placebo, along with the maintenance of efficacy of 
secukinumab at W eek 52 in subjects with moderate to severe HS. Moreover, this study 
will also assess the safety and tolerability of secukinumab.
Primary  
Objective(s) The primary objective of this study is to demonstrate the efficacy of secukinumab 
compared to placebo with respect to HiSC R after [ADDRESS_37296] to:
● percentage change in AN count
● proportion of patients with HS flares
● proportion of patients with clinical response in HS related skin pain after 16 weeks of 
treatment
Study  design This is a multicenter, randomized, double -blind, placebo controlled, parallel group study 
with two secukinumab dose regimens in approximately 541patients with moderate to 
severe HS. The study consists of: Screening (up to 4 weeks), Treatment Period 1 (16 
weeks) and Treatment Period 2 (36 weeks). Subjects who prematurely discontinue the 
study, or who complete the study and cannot or do not wish to continue in a planned 
optional extension study, will enter a post -treatment Follow -Up period (8 weeks).
Population The study population will consist of a representative group of adult male and female 
subjects (≥ 18 years) with moderate to severe HS. It is aimed to randomize approximately 
541subjects i n approximately 132 study sites worldwide. Up to 40% of the subjects will 
be allowed to enter the study on treatment with stable dose of antibiotics.
Key Inclusion 
criteria1. Written informed consent must be obtained before any assessment is performed.
2. Male and female patients ≥ 18 years of age.
3. Diagnosis of HS ≥ 1 year prior to baseline.
4. Patients with moderate to severe HS defined as:
● A total of at least 5 inflammatory lesions, i.e. abscesses and/or inflammatory 
nodules
AND
● Inflammatory lesions should affect at least [ADDRESS_37297] anatomic areas
5. Patients agree to daily use of topi[INVESTIGATOR_37184] -the-counter antiseptics on the areas affected 
by [CONTACT_37219].
Key Exclusion 
criteria1. Total fistulae count ≥ 20 at baseline.
2. Any other active skin disease or condition that may interfere with assessment of HS.
3. Active ongoing inflammatory diseases other than HS that require treatment with 
prohibited medications (see Table 6 -2).
4. Use or planned use of prohibited treatment. W ashout periods detailed in the protocol 
have to be adhered to (see Table 6 -2).
5. History of hypersensitivity to any of the study drug constituents.
6. History of lymphoproliferative disease or any known malignancy or history of 
malignancy of any organ system treated or untreated within the past 5 years, regardless 
of whether there is evidence of local recurrence or metastases (except for skin Bowen’s 
disease, or basal cell carcinoma or actinic k eratoses that have been treated with no 
evidence of recurrence in the past 12 weeks; carcinoma in situ of the cervix or non -

[COMPANY_001] Confidentia l Page 17
Amended Protocol Version 02 ( Clean ) Protocol No. CAIN457M2301
invasive malignant colon polyps that have been removed).
7. Pregnant or lactating women.
Study  treatment ● Secukinumab 300 mg solution for s.c. injection in a 2 ml PFS
● Placebo solution for s.c injection in a 2 ml PFS
Efficacy  
assessmentsEfficacy assessments related to the primary and secondary objectives include:
● Individual lesion count used for calculation of Hidradenitis Suppurativa Clinical 
Response (HiSCR) and HS flare
● Patient's Global Assessment of Skin Pain -NRS in the past 24 hours
Key safety  
assessments● Evaluation of all AEs and SAEs
● Physical examination
● Vital signs
● Laboratory evaluations (e.g. hematology , clinical chemistry, urinalysis)
● Immunogenicity (assessment of anti -AIN457 antibody development)
● Pregnancy
Other 
assessments ● Additional efficacy assessments linked to the exploratory objectives include: 
● Modified Hidradenitis Suppurativa Score (mHSS);
● HS-Physician's Global Assessment (HS -PGA);
● Dermatology Life Quality Index (DLQI);
● Health Status Questionnaire (EQ-5D -3L);
● Patient Global Impression of severity (PGI -s);
● Patient Global Impression of change (PGI -c);
● Work Productivit y and Activity Impairment -Specific Health Problem (W PAI-SHP);
● HS Symptom Diary
● Exploratory biomarkers
● Pharmacokinetic parameter
Data analy sis The primary endpoint of the study is HiSCR at Week 16, defined as at least a 50% 
decrease in the Abscess and inflammatory Nodule (AN) count compared to baseline with 
no increase in the number of abscesses and/or in the number of draining fistulae from 
baseline to Week 16.
The secondary endpoints of this study are as follows:
● Percentage change from baseline in AN count at W eek 16
● Flare over 16 weeks: Patients who experience at least one flare over [ADDRESS_37298] a 25% increase in AN count with a minimum increase of 2 AN relative 
to baseline.
● Pain/NRS30 at W eek 16: Patients achievi ng NRS30 at W eek 16, among patients with 
baseline NRS ≥ 3. NRS30 is defined as at least a 30% reduction and at least 2 unit 
reduction from baseline in the Patient's Global Assessment of Skin Pain.
The statistical hypothesis for the primary endpoint being t ested is that there is no 
difference in the proportion of HiSCR at W eek 16 in any of the secukinumab regimens 
versus placebo regimen.
H1: secukinumab [ADDRESS_37299] to 
HiSCR after 16 weeks of treatment.
H2:secukinumab [ADDRESS_37300] to 
HiSCR after 16 weeks of treatment.
The primary analysis method will be logistic regression with treatment group, 
geographical region, Hurley stage, use of antibiotic, baseline body weight and baseline 
AN count as explanatory variables. Odds ratios will be computed for comparisons of 
secukinumab dose regimens versus placebo utilizing the logistic regression model fitted. 
In case of response rates of 0% or of 100% in one of the t reatment groups, Fisher’s exact 
test will be applied. Risk difference and confidence intervals for risk difference will be 
provided.
The statistical hypotheses for the secondary endpoint being tested are that:
● there is no difference in mean of percentage change from baseline in AN count in any 
of the secukinumab regimens versus placebo regimen
● there is no difference in the proportion of flare over 16 weeks in any of the secukinumab 
regimens versus placebo regimen
● there is no difference in the proporti on of NRS30 at W eek 16 in any of the secukinumab 
regimens versus placebo regimen

[COMPANY_001] Confidentia l Page 18
Amended Protocol Version 02 ( Clean ) Protocol No. CAIN457M2301
H3: secukinumab [ADDRESS_37301] to the 
percentage change from baseline in AN count at W eek 16
H4: secukinumab [ADDRESS_37302] to the 
percentage change from baseline in AN count at W eek 16
H5: secukinumab [ADDRESS_37303] to flare 
over 16 weeks of treatment
H6: secukinumab [ADDRESS_37304] to flare 
over 16 weeks of treatment
H7: secukinumab [ADDRESS_37305] to 
NRS30 at W eek 16
H8: secukinumab [ADDRESS_37306] to 
NRS30 at W eek 16
For the secondary endpoint of percentage change in AN count from baseline to W eek 16, 
an analysis of covariance (ANCOVA) model will be fitted to estimate the treatment 
differences between the two secukinumab regimens and placebo with treatment group, 
baseline AN count, Hurley stage, use of antibiotic, geographical region and baseline body 
weight as covariates
The analysis method for flare up to Week 16 and Pain/NRS30 at Week 16endpoints will 
be the logistic regression: w ith treatment group, Hurley stage, geographical region, use of 
antibiotic, baseline body weight and baseline AN counts as explanatory variables for flare 
endpoints; and with treatment group, Hurley stage, region, use of antibiotic, baseline body 
weight andbaseline NRS as explanatory variables for pain endpoints. Odds ratios will be 
computed for comparisons of secukinumab dose regimens versus placebo utilizing the 
logistic regression model fitted. In case of response rates of 0% or of 100% in one of the 
treatment groups, Fisher’s exact test will be applied. Risk difference and confidence 
intervals for risk difference will be provided .
Key words hidradenitis suppurativa, HS, IL -17A, monoclonal antibody, AIN457, secukinumab, 
HiSCR, pain, efficacy, safety

[COMPANY_001] Confidentia l Page 19
Amended Protocol Version 02 ( Clean ) Protocol No. CAIN457M2301
1 Introduction
1.1 Background
Hidradenitis suppurativa (HS), also called “acne inversa” or “maladie de Verneuil”, is a chronic, 
recurrent, and debilitating inflammatory  skin condition that typi[INVESTIGATOR_37185], 
inflammatory , painful lesions in apocrine gland- bearing parts of the body . The most common 
areas affected are the axillae, the groin, and the anogenital region (Fimmel andZouboulis 2010 ,
Jemec 2012 ).
HS is currently  considered an inflammatory  disease of the pi[INVESTIGATOR_37186] y predisposed individuals 
(Kelly et al 2014 ).
The disease starts after puberty  and women are more frequentl y affected than men (3:1). Risk 
factors include obesit y and smoking. Although epi[INVESTIGATOR_37187]  (0.03 to 4.3%), and geographical differences exist, a prevalence of approximately  0.1 to 
1% is accepted b y the scienti fic community  (Deckers et al 2014 ,Garg et al 2017 ).
The clinical manifestations of HS are heterogeneous, but the disease tends to manifest with 
chronic, relapsing, deep, painful, inf lammatory  skin lesions, mostly  inflammatory  nodules and 
abscesses, leading to possible drainage and suppuration. Inflammatory  lesions are complicated 
during disease progression by [CONTACT_37220], and may lead to 
hypertrophic scarring with a possible impact on functional use.
HS is associated with pain, malodorous discharge from the wounds, and scarring, and it 
frequentl y has devastating psy chosocial effects. HS is a profoundly  debilitating disease with a 
high negative impact on qual ity of life (QoL), with multiple studies confirming that the impact 
is greater than that seen with other dermatologic diseases (Deckers andKimball 2016 ). Patients 
with HS also often suffer from depression, social isola tion, have an impaired sexual health, and 
may have difficulty  performing their work duties ( Deckers et al 2014 , Janse et al 2017 ).
HS is difficult to treat. Official European treatme nt guidelines have only been developed in 
[ADDRESS_37307] that patients should be provided with adjuvant, medical and surgical therapy  
(Zouboulis et al 2015 ).
While topi[INVESTIGATOR_37188], long courses of multiple antimicrobial 
therap y are preferred for moderate to severe HS, generall y with tetracy clines or a combination 
of clindam ycin and rifampi[INVESTIGATOR_2513], which can be followed by  [CONTACT_37221] (Zouboulis et al 2015 , Bettoli et al 2016 , 
Dessinioti et al 2016 ).
However, it is widely  recognized that HS is a chronic inflammatory  condition, not an infectious 
disease (Jemec 2012 ). Therefore, anti-inflammatory  agents are an alternative and probabl y 
more appropriate approach than antibiotics.
Over time, the consequence of chronic, recurrent, inadequatel y treated inflammation is 
irreversible fibrosis, which does not respond to medical therapy . Once lasting anatomical 
changes occur, the onl y therapeutic option to reduce the volume of fibrotic tissue and improve 
functionality  in the areas of affected skin is surg ery (Andersen andJemec 2017 ).

[COMPANY_001] Confidentia l Page 20
Amended Protocol Version 02 ( Clean ) Protocol No. CAIN457M2301
In 2015, adalimumab (Humira®), a recombinant human monoclonal immunoglobulin G1 (IgG1) 
antibody  to soluble and membrane bound tumor necrosis factor α (TNF -α), received regulatory 
approval for the treatment of moderate to severe HS.
Efficacy  has been seen with adalimumab, with Hidradenitis Suppurativa clinical response 
(HiSCR) response rates over placebo of approximately  16% (41.8% adalimumab vs 26% 
placebo) and 31% (58.9% adalimumab vs 27.6% placebo) as reported in PI[INVESTIGATOR_15597] I and II 
studies, respectivel y (Kimball et al 2016 ). As captured in the adalimumab labels, adalimumab 
is associated with an increased safet y risk for serious infections including tuberculosis (TB), 
invasive fungal infections and other opportunistic infections. An increased incidence of 
malignancies has also been reported with adalimumab.
There is an unmet need for systemic therapie s that effectivel y reduce inflammation while having 
a favorable safet y profile.
Secukinumab (AIN457) is a recombinant high-affinity  fully human monoclonal anti-human 
interleukin -17A (IL-17A) antibody  of the immunoglobulin G1 (IgG1)/kappa isoty pe. 
Secukinum ab is selective for human IL-17A and potently  neutralizes the bioactivity  of this 
cytokine. IL -17A is the central cy tokine in multiple autoimmune and inflammatory  processes.
In HS, there is increasing scientific evidence to support the role of IL -17 in the pathogenesis of 
the disease:
Upregulation of mRNA for IL -17A in lesions of patients with HS and psoriasis, while 
levels in control and atopic dermatitis patients were not increased ( Wolk et al 2011 )
High levels of IL-1 7A or downstream markers are expressed in inflammatory  HS lesions 
(Kelly et al 2015 , Lima etal2016 ): 
IL-17 producing cells are present in lesional and peri -lesional HS skin and ma y 
contribute to the initiation of inflammatory  processes.
Massive influx of IL -17-expressing cells (neutrophils and/or T -lymphocy tes) has been 
observed in deep dermal infiltrates.
Increased IL- [ADDRESS_37308] been observed in patients with HS; a tende ncy toward 
higher serum concentrations of IL -17 has been reported for patients with more advanced 
disease ( Matusiak et al 2016 ).
Secukinumab is approved in more than [ADDRESS_37309] received secukinumab in clinical studies at doses 
ranging from single and/or multiple doses of 0.1 mg/kg to 30 mg/kg intravenous (i.v.) and 25 
mg to 300 mg subcutaneous (s.c.) (Investigator's Brochure (IB) Edition 20, data cut-off 25-Jun-
2020 ). The cumulative patient exposure from post-marketing experience for all approved 
indications since the International Birth Date of the product is approximately 467,835 patient-
treatment years (PTY) (Periodic Safet y Update Report (PSUR), data cut-off 25-Dec-2019 ). Full 
safet y results including all reported adverse events (AEs) are currently available for completed 
studies across different indications. In general, these r esults show comparable numbers of AEs 
in subjects treated with secukinumab compared to placebo without indication of any specific 

[COMPANY_001] Confidentia l Page 21
Amended Protocol Version 02 ( Clean ) Protocol No. CAIN457M2301
organ toxicity . The Investigator’s Brochure (IB) provides a more detailed review of the pre-
clinical and clinical information on secukinumab.
In a case report by [CONTACT_37222], substantial improvement was observed in the number of boils 
and pain severit y in one patient with HS treated with secukinumab 300 mg ever y 4 weeks, after 
loading doses of 300 mg weekly for 4 weeks (Thorlacius et al 2017 ). A second case report 
described a patient treated with secukinumab who experienced significant improvement with 
secukinumab in a similar dosing regimen ( Schuch et al 2018) further supporting that treatment 
with an anti-IL-[ADDRESS_37310] case report 
(Pandey et al 2018 ) described a patient with HS who responded to secukinumab treatment for 
a per iod of 6 months and was able to discontinue treatment after satisfactor y improvement. The 
patient remained symptom free for three months following discontinuation, and began 
successful re-treatment with secukinumab after lesions reappeared. No unexpected safety 
signals were observed in all three patients.
Early clinical evidence of the effects of another [COMPANY_001] anti-IL-17 antibody , CJM112, 
supports the potential of an anti-IL-17 antibody  as an effective therapy  for patients with HS. 
The results of a rando mized, double -blind, placebo -controlled Phase 2 study in 66 patients with 
moderate to severe HS (study  CCJM112X2202) showed a statistically  significant increase in 
the responder rate (HS Physician's Global Assessment (HS-PGA) responder rate 32.3% vs 
12.5%, p = 0.028) at Week 16. 
Numerical decreases in inflammatory  lesions were similar to 
that observed with adalimumab ( -2.6 inflammatory  lesions in CJM112 relative to placebo vs -
2.4 to - 3.0 in adalimumab relative to placebo) ([COMPANY_001] data on file).
Based on the available data, secukinumab has the potential to be an effective therapy  for 
moderate to severe HS with efficacy  at least similar to that of adalimumab, a better safet y profile 
and sustained low immunogenicity  supporting long -term treatment.
The aim of the present study  is to assess the efficacy , safet y, pharmacokinetics and tolerability  
of two dose regimens of secukinumab in patients with moderate to severe HS.
1.2 Purpose
The purpose of this study  is to demonstrate superiority  of secukinumab at Week 16, b ased on 
HiSCR rates versus placebo, along with the maintenance of efficacy  of secukinumab at 
Week 52 in subjects with moderate to severe HS. Moreover, this study  will assess the safet y 
and tolerability  of secukinumab.
2 Objectives and endpoints
Table 2-1 Objectives and related endpoints
Objective(s) Endpoint(s)
Primary  objective(s) Endpoint(s) for primary  objective(s)
● To demonstrate the efficacy of secukinumab 
compared to placebo with respect to HiSCR after 
16 weeks of treatment.● Achievement of HiSCR at Week 16. HiSCR is defined as 
at least a 50% decrease in Abscess and Inflammatory 
Nodule (AN) count with no increase in the number of 
abscesses and/or in the number of drai ning fistulae.

[COMPANY_001] Confidentia l Page 22
Amended Protocol Version 02 ( Clean ) Protocol No. CAIN457M2301
Objective(s) Endpoint(s)
Secondary  objective(s) Endpoint(s) for secondary  objective(s)
● To demonstrate the efficacy of secukinumab 
compared to placebo after [ADDRESS_37311] to AN count.
● To demonstrate the efficacy of secukinumab 
compared to placebo after [ADDRESS_37312] to:
● proportion of patients with HS flares
● proportion of patients with clinical response 
in HS related skin pain● Percentage change from baseline in AN count at W eek 
16.
● Flaring up to W eek 16. Flare is defined as at least a 25% 
increase in AN count with a minimum increase of 2 AN 
relative to baseline.
● Achievement of NRS30 at Week 16, among subjects with 
baseline NRS ≥ 3. NRS30 is defined as at least a 30% 
reduction and at least 2 unit reduction from baseline in 
Patient's Global Assessment of Skin Pain -at worst.
Exploratory  objective(s) Endpoint(s) for exploratory  objective(s)
● To evaluate the safety and tolerability of 
secukinumab over 52 weeks of treatment.● Clinical safety and tolerability assessments:
● physical exams,
● vital signs,
● laboratory assessments,
● AE monitoring
● To explore the long -term effect of 
secukinumab with respect to HiSCR, AN count, 
proportion of patients with flares, HS related skin 
pain up to 52 weeks of treatment.● Achievement of clinical response as defined by [CONTACT_37223].
● Absolute and percentage change from baseline in AN 
count.
● Flares
● Achievement of pain relief as defined by [CONTACT_37224]30.
● To evaluate the effect of secukinumab with 
respect to the followi ng efficacy assessments:
● Modified Hidradenitis Suppurativa Score 
(mHSS);
● HS-Physician's Global Assessment (HS -
PGA);
● Dermatology Life Quality Index (DLQI);
● Health Status Questionnaire (EQ-5D -3L);
● Patient Global Impression of severity (PGI -
s);
● Patient Global Impression of change (PGI -
c);
● Work Productivity and Activity Impairment 
(WPAI);
● HS Symptom Diary
● Inflammatory markers with respect to CRP 
and ESR 
compared to placebo after 16 weeks ,and in the 
two secukinumab dose regimens up to 52 weeks 
of treatment.● Absolute and percent change from baseline in modified 
Hidradenitis Suppurativa Score (mHSS).
● HS-PGA response. HS -PGA response is defined as the 
achievement of at least a 2 -point reduction in HS -PGA 
score compared to baseline.
● DLQI response and absolute/percent DLQI total score 
change from baseline.
DLQI response is defined as a decrease greater than 5.0 
points from baseline.
● EQ-5D-3L Categories on Category questions and 
summary statistics on EQ -5D -3L score questions.
●Patient Global Impression of severity and change (PGI -s 
and PGI -c) categories.
● Absolute and percent change from baseline in W ork 
Productivity and Activity Impairment -Specific Health 
Problem ( WPAI-SHP).
● HS Symptom Diary items score change from basel ine.
● Absolute and percent change from baseline in CRP and 
ESR.
● To evaluate the pharmacokinetics of 
secukinumab in HS patients.● AIN457 levels in serum
● To assess the development of immunogenicity 
against secukinumab.● anti-AIN457 antibodies levels in serum
● To explore the potential association of 
biomarker levels with secukinumab efficacy and 
safety by [CONTACT_37225] 52 visit (EOT2) .● Biomarkers in serum

[COMPANY_001] Confidentia l Page 23
Amended Protocol Version 02 ( Clean ) Protocol No. CAIN457M2301
Objective(s) Endpoint(s)
●To explore the efficacy of secukinumab 
compared to placebo with respect to HiSCR 
response after 16 weeks of t reatment and the 
sustained efficacy over time in bio -naive 
patients.
● To explore the efficacy of secukinumab 
compared to placebo with respect to HiSCR 
response after 16 weeks of treatment and the 
sustained efficacy over time in patients with body 
weight lower andhigher than 90 kg (90 kg and 
≥90 kg) .● Achievement of HiSCR at Week 16 and up to Week 52 in 
bio-na ive patients.
● Achievement of HiSCR at Week 16 and up to Week 52 in 
patients with body weight lower and higher than 90 kg(90
kg and ≥90kg).

[COMPANY_001] Confidentia l Page 24
Amended Protocol Version 02 ( Clean ) Protocol No. CAIN457M2301
3 Study  design
This is a multicenter, randomized, double -blind, placebo controlled, parallel group study  with 
two secukinumab dose regimens in approximately  541 patients with moderate to severe HS.
The study  consists of: Screening (up to 4 weeks), Treatment Period 1 (16 weeks) and Treatment 
Period 2 (36 weeks). Subjects who prematurel y discontinue the study , or who complete the 
study  and cannot or do not wish to continue in a planned optional extensi on study , will need to 
complete a post -treatment Follow -Up period (8 weeks). 
Safety , efficacy , biomarker and pharmacokinetic measurements of secukinumab will be 
assessed.
An outline of the study  design is presented in Figure 3-1, and a detailed visit and assessment 
schedule is provided in Table 8 -1.
Screening (Screening to Randomization)
A screening period of up to [ADDRESS_37313]´s eligibility  and to 
washout and/or taper prohibited medication(s). Two screening visits will be performed: Visit 1 
(Day  -28 to Da y -14) and Visit 2 (Day -13 to Da y -1). Subjects can be re -screened if the subject 
screen fails due to a transient medical condition or due to an insufficient prohibit ed medication 
washout period. Subjects can be re-screened only once and no study -related re-screening 
procedure should be performed prior to re -consenting the subject.
Important note:
In the event of a global health disruptive event, such as pandemic/epi[INVESTIGATOR_37189], Investigators 
should only randomize patients if they expect them to be able to adhere to assessments and 
protocol -related activities. Evaluation of theeligibility  of the subject should consider the abilit y 
to attend study  visits and adhere to protocol assessments. If the latter is not anticipated, 
screening and randomization should not proceed, and re -screening (as allowable per protocol –
see above) sh ould be considered when conditions allow for proper trial management.
Treatment Period 1 (Randomization to Week 16 pre -dose)
Treatment Period 1 covers the time from randomization (baseline) through Week 16 (prior to 
Week 16 dosing). At baseline, eligible subjects will be randomized at a 1:1:0.5:0.5 ratio to one 
of four treatment arms:
Secukinumab 300 mg every  2 weeks
Secukinumab 300 mg every  4 weeks
Placebo group to secukinumab 300 mg every  2 weeks
Placebo group to secukinumab 300 mg every  4 weeks
Approxim ately  180patients will be randomized to each of the two secukinumab regimen arms 
and another 180patients will be randomized to two placebo switching to secukinumab regimen 
arms. 

[COMPANY_001] Confidentia l Page 25
Amended Protocol Version 02 ( Clean ) Protocol No. CAIN457M2301
In the event of a global health disruptive event, such as pandemic/epi[INVESTIGATOR_37190] a potential increase in the number of missing measurements, the Sponsor may 
consider recruiting additional patients to restore thesample size and maintain the pre-defined 
statistical power.
Randomization will be stratified b y region, current antibiotic use and bod y weight. All subjects 
will receive a single s.c. injection of blinded study  drug (active drug or placebo) once a week 
for four weeks (induction) at Baseline, Week 1, 2, 3 and 4.Thereafter, the frequency  of study 
drug injections will be every  2 weeks for all subjects in order to maintain the treatment blind: 
either placebo (placebo to secukinumab arms), or secukinumab alternating with placebo every 
2 weeks (secukinumab 300 mg every  4  w eeks arm) or secukinumab every  2  w eeks 
(secukinumab 300 mg every  2 weeks arm). See Figure 3-1.
In Treatment Period 1, home administrations (H)of study  drug are scheduled at Weeks 6, 
10 
and 14.
Refer to Section 6.1.3 for further details on treatment arms.
Subjects who complete Treatment Period 1 will enter Treatment Period 2.
Treatment Period 2 (Week [ADDRESS_37314] -dose to Week 52)
Treatment Period 2 is defined as the time from Week 16 (post -dose) through Week 52. From 
Week 16, all patients will receive secukinumab.
The Week [ADDRESS_37315] dose of Treatment Period 2.
Subjects who were randomized to either of the two secukinumab regimens will continue on the 
same dose regimen. Subjects who were randomized to one of the two 'Placebo to secukinumab' 
regimens will receive either secukinumab 300 mg ever y 2 weeks or secukinumab 300 mg every 
4 weeks.
At Week 16, all subjec ts will receive a re-induction consisting of a single s.c. injection of 
blinded study  drug (active drug or placebo) once a week for four weeks , at Week 16, 17, 18, 19 
and 20. Thereafter, all subjects will receive study  drug injections every  2  w eeks, either
secukinumab alternating with placebo every  2 weeks (secukinumab 300 mg every  4 weeks arm) 
or secukinumab every  2 weeks (secukinumab 300 mg every 2 weeks arm) until Week 50.
Home administrations (H)of study  drug are scheduled at Weeks 22, 26, 30, 34, 38, 42, 46 and 
50.
The planned end of Treatment Period 2 visit (EOT 2) will be performed at Week 52. At this 
visit, the site should call Interactive Response Technology  (IRT) after performing the scheduled 
study  assessments to record the completion of treatment period by [CONTACT_1130](s). For subjects 
rolling over to the extension study , Week 52 will be the end of study  visit; for subjects 
continuing to the Post -Treatment Follow -Up, the visit at Week 60 will be the end of study visit. 
Subjects who discontinue study  treatment prematurely  for any  reason other than withdrawal of 
informed consent before Week 52 should not be considered as discontinued from the study . 
Subjects should continue attending site visits for the study  assessments. Subjects who are 
unwilling to continue attending further study  visits after discontinuing the study  drug, should 

[COMPANY_001] Confidentia l Page 26
Amended Protocol Version 02 ( Clean ) Protocol No. CAIN457M2301
attend the end of study  visit. The End of Treatment visit (EOT 1 for discontinuation during 
Treatment Period 1 and EOT 2 for discontinuation during Treatment Period 2) which should be 
performed two weeks (where possible) after their last dose of study  drug. After the EOT visit, 
subjects should enter the post- treatment Follow -Up period.
If the primary  endpoint analy sis conducted after all subjects complete Week 16 shows a posit ive 
benefit -risk for only one of the two dose regimens evaluated in the study (e.g. no significant 
effect on primary  and secondary  endpoints is observed for one of the proposed dose regimens), 
patients still participating in Treatment Period [ADDRESS_37316] -Treatment Follow-Up (8 weeks)
Only subjects who prematurely discontinue study  treatment in Treatment Periods [ADDRESS_37317]-
Treatment Follow-Up and complete the Week 60 (F8) visit (see Table 8-1).
Figure 3-1 Study  design
BSL: Baseline; EOT1/E OT2: End of Treatment 1/2; F8: End of Follow -up visit at W eek 60; q2w : every 
two weeks; q4w: every four weeks. Treatment allocation for Placebo arm switching to secukinumab 
arms at Week 16 will be performed at the Randomization visit in 1:1 ratio and does not account for 
potential discontinuations during Treatment Period 1. Follow -up: only subjects who prematurely 
discontinue treatment during Treatment Period 1 or 2 or subjects who do not enroll in the extension 
study, will enter Follow -up. 
In the event of a global health disruptive event, such as a pandemic/epi[INVESTIGATOR_901] (e.g. COVID -19), that 
limits or prevents the conduct of site study visits per protocol, special effort should be made to conduct 

[COMPANY_001] Confidentia l Page 27
Amended Protocol Version 02 ( Clean ) Protocol No. CAIN457M2301
on-site visits for the EOT(s) visits, Week [ADDRESS_37318] these visits on 
site, virtual visits, or visits to the patient´s home should be attempted.
Delay  of Week 52 visit (special scenario)
In the event Week 52 cannot be performed on-site as scheduled due to a global health disruptive 
event, such as a pandemic/epi[INVESTIGATOR_901] (e.g. COVID-19), or to a delay  of HAs/ECs approval of the 
extension protocol, an additional treatment period of up to a maximum of 12 weeks (i.e., up to 
6 doses, the frequency of study  drug injections wil l remain ever y 2 weeks) could be considered 
to ensure therapeutic continuity  for the patients until they  are able to perform Week 52 visit on -
site, and then participate in  the long -term extension study . See Figure 3 -
2.
Figure 3-2 Study  design in case of global health disruptive event
*UNS = Unscheduled; UNS1, UNS2 and UNS3 correspond to three possible additional IRT calls at 
which 2 doses will be dispensed.
4 Rationale
4.1 Rationale for study  design
The double- blind, randomized, parallel -group, placebo -controlled design will enable the 
evaluation of the benefit -risk of the two proposed secukinumab dose regimens in an adequate 
and well- controlled setting.

[COMPANY_001] Confidentia l Page 28
Amended Protocol Version 02 ( Clean ) Protocol No. CAIN457M2301
The primary and secondary endpoints reflect the most important domains in HS as proposed by 
[CONTACT_37226]  (Thorlacius et al 2018 ). The primary  endpoint used in this study , 
HiSCR, was developed and validated in the context of the development program of adalimumab 
in HS. The HiSCR is considered to be adequately  described and validated for its intended 
purpose as the primary  endpoint in pi[INVESTIGATOR_37191] y been the basis f or the HA 
approval of adalimumab as a treatment for patients with moderate to severe 
HS(Humira (adalimumab) EPAR ).
AN count, n umber of flares ,and reduction in skin pain are selected as secondary endpoints due 
to their impact on patient’s quality  of life. These endpoints will provide complementary 
clinically  relevant information not fully  evaluated in the primary  endpoint, HiSCR.
The primary  endpoint will be evaluated at Week 16, which is the maximal acceptable duratio n 
of treatment exposure to placebo in this indication (see Section 4.3 for further rationale on the 
use of placebo). The total study  duration including one year of treatment will allow for 
assessment of long -term safet y and s ustainabilit y of the effect in the two dose regimens.
Adult subjects with moderate to 
severe HS will be included in the study . Moderate to severe 
HS will be defined as having at least [ADDRESS_37319] affected area as in the previously  used Hurle y 
Stages.
The proposed 
number of inflammatory  lesions assures that patients would meet the definition 
of moderate to severe disease in the broadl y used HS-PGA tool as proposed by [CONTACT_37227] 
(Alavi 2016 ). It is also in line with the proposed refined Hurley  Staging ( Horv áthet al 2017 ), 
which proposes that selecting the population by [CONTACT_37228] [ADDRESS_37320]  to define patients with moderate to severe HS who 
should be candidates for treatment with biologic anti-inflammatory  therapi[INVESTIGATOR_014]. Using this 
definition for moderate to severe HS it is expected that the study  will mainly  include patients 
in Hurley  stages II and III, but will still allow a small proportion of patients with highly  
inflammatory  Hurley  stage I to enter the study . Based on available data, it is expected that the 
proportion of Hurley  stage I patients in the proposed studies will be less than 15% of the 
recruited patients in this study .
Patient's previous treatment failure to antibiotics is not a requirement to enter the study . It is 
expected that the majority of the patients entering the study  would have previously  received 
systemic antibiotics at least during the period since diagnosis ( ≥ 1 y ear).
Reflecting the clinical practice in man y countries and the concern of exposing some patients to 
placebo for up to [ADDRESS_37321] 
previously  failed to respond to this treatment approach. It is expected that patients who 
previously  failed to respond to sy stemic antibiotics will enter the study  without chronic u se of 
systemic antibiotics (non-antibiotic strata). Information on the previous use of systemic 
therapi[INVESTIGATOR_37192].

[COMPANY_001] Confidentia l Page 29
Amended Protocol Version 02 ( Clean ) Protocol No. CAIN457M2301
Patients with 20 or more fistulas at baseline will not be eligible for the study  as the high level 
of scarring expected in these patients could significantly  impair the ability  to accuratel y count 
the number of inflammatory  lesions for the primary  and secondary  endpoint.
4.2 Rationale for dose/regimen and dura tion of treatment
Two secukinumab dosing regimens will be evaluated in this study :
Secukinumab 300 mg s.c. every  4 weeks
Secukinumab [ADDRESS_37322] labelling for moderate to severe plaque 
psoriasis. Initial information from case reports shows a positive clinical response to treatment 
in patients with HS treated with the psoriasis therapeutic dose (Thorlacius et al 2017 ; 
Schuch et al 2018 ). The demonstrated positive benefit -risk of the 300mg s.c. every  4 weeks 
regimen in psoriasis, another inflammatory  dermatological disease, supported by [CONTACT_37229] a positive benefit -risk in HS and justifies further evaluation in this study .
Rationale for 300 mg s.c. every 2 w eeks regim en
In addition to the psoriasis dose regimen, the second dose regimen will be evaluated to achieve 
a higher exposure for the following reasons:
Higher bod y weights are expected for this population compared to the psoriasis population 
(approximately  10 kg heavier weight for HS population in clinical trials 
(Kimball et al 2016 )), thus potentially  requiring higher doses to achieve adequate 
exposure. Secukinumab systemic exposure varies with body  weight in an allometric 
relationship. For clearance, the allometric exponent was estimated to be close to 1; in 
other words, a doubling of body  weight could lead to a nearl y 2-fold increase in clearance 
and therefore reduced serum exposure ( Bruin et al 2017 ). Therefore, evaluation of a 
dosing regimen with higher exposure than that resulting from the marketed regimen is 
appropriate in this heavier patient population.
Higher local exposure than in psoriasis might be needed for this disease with deep
inflammatory  subcutaneous lesions.
Clinical experience with adalimumab in HS supports a dosing regimen with higher 
exposure in HS than in psoriasis.

[COMPANY_001] Confidentia l Page 32
Amended Protocol Version 02 ( Clean ) Protocol No. CAIN457M2301
Neutropenia and h ypersensitivity  reactions are also risks observed with sec ukinumab. Cases of 
neutropenia were uncommon, generally mild to moderate, transient, did not lead to treatment 
discontinuation, and only a few cases were temporally  associated with non- serious infections.
Secukinumab [ADDRESS_37323] 24 weeks. This 
included over 200 patients with psorias is.The safety  profile observed in the available data is 
consistent with the known safet y profile of secukinumab.
Treatment with multiple high doses of secukinumab (10 mg/kg and 30 mg/kg i.v.) has been 
administered to more than 2000 patients, with the majority  receiving 3 doses of 10 mg/kg i.v. 
over [ADDRESS_37324] 6 months. Treatment with 
high doses (monthl y exposure on chronic doses being approximately  2-fold higher compared 
to 300 mg s.c. every  2 weeks dose) was associated with a numerical increase in infections 
compared to placebo, mainly  due to more reports of non-serious upper respi[INVESTIGATOR_37193], but also a few more individual reports of non -serious local fungal infections such as 
oral or vulvovagi nal candidiasis. Otherwise, the safet y profile was consistent with the known 
safet y profile of secukinumab with the approved doses.
The recentl y completed randomized, double -blind, multicenter study  CAIN457A2324 
([STUDY_ID_REMOVED]), evaluated the safet y and efficacy of secukinumab 300 mg s.c. administered 
every  2 w eeks (q2w) or every  4 w eeks (q4w), in patients with psoriasis who weigh ≥90 kg. 
Study  CAIN457A2324 showed that in psoriasis patients who weigh ≥90kg, secukinumab 
[ADDRESS_37325] the efficacy  data is not yet published 
at the time of release of protocol amendment 02, the analy sis of the safet y data did not 
demonstrate an y new safety signals with the q2w regimen and showed an over all safet y profile 
in line with what is already  known.
The risk to subjects in this trial may be minimized by [CONTACT_5345], as well as close clinical monitoring, and periodic review of safet y data 
by [CONTACT_37230].
Based on all available data, and a positive benefit/risk ratio for the treatment of moderate to 
severe HS with secukinumab at doses [ADDRESS_37326] of a representative group of adult male and female patients ( ≥ 
18 years old) with moderate to severe HS. The study  originally aimed to randomize 
approximately  [ADDRESS_37327] of the study  since the release of 
protocol amendment 01, the number of randomized patients was increased to approximatel y 
541(15increase f rom the original population of 471 patients). Up to 40% of the patients will 
be allowed to enter the study on treatment with stable dose of antibiotics. Patients who drop out 
after they  have been randomized will not be replaced.

[COMPANY_001] Confidentia l Page 33
Amended Protocol Version 02 ( Clean ) Protocol No. CAIN457M2301
In case of a global health disruptive event, such as pandemic/epi[INVESTIGATOR_37194], patients or sites may not be able to perform the assessments as per protocol, leading 
to a potential increase in the number of missing measurements. If the latter should affect the 
power of tests and the precision of estimates for this study , the Sponsor may consider recruiting 
additional patients to restore the sample size and maintain the pre -defined statistical power. 
5.[ADDRESS_37328] meet allof the following criteria:
1.Written informed consent must be obtained before any  assessment is performed.
2. Male and female patients ≥ 18 y ears of age.
3.Diagnosis of HS ≥ 1 y ear prior to baseline.
4.Patients with moderate to severe HS defin ed as:
A total of at least 5 inflammatory  lesions, i.e. abscesses and/or inflammatory  nodules
AND
Inflammatory  lesions should affect at least [ADDRESS_37329] anatomic areas
5.Patients agree to daily  use of topi[INVESTIGATOR_37184]-the-counter antiseptics on the areas affecte d by 
[CONTACT_37231].
5.2 Exclusion criteria
Patients meeting an y of the following criteria are not eligible for inclusion in this study .
1.Total fistulae count ≥ 20 at baseline.
2.Any other active skin disease or condition that may  interfere with assessment of HS.
3.Active ongoing inflammatory diseases other than HS that require treatment with prohibited 
medications (see Table 6 -2).
4.Underl ying conditions (including, but not limited to metabolic, hematologic, renal, h epatic, 
pulmonary , neurologic, endocrine, cardiac, infectious or gastrointestinal such as 
inflammatory  bowel disease ) which in the opi[INVESTIGATOR_37195] y 
immunocompromises the patient and/or places the patient at unacceptable risk for receiving 
an immunomodulatory  therapy .
5.Current severe progressive or uncontrolled diseases which renders the patient unsuitable for 
the trial or puts the patient at increased risk, including an y medical or ps ychiatric condition 
which, in the Investigator’s opi[INVESTIGATOR_1649], would preclude the participant from adhering to the 
protocol or completing the study  per protocol.
6.Use or planned use of prohibited treatment. Washout periods detailed in the protocol have 
to be adhered to (see Table 6 -2).
7.For patients enrolling in the non-antibiotic strata: use of systemic antibiotics for the 
treatment of HS within 28 day s before baseline.
For patients enrolling in the antibiotic strata: patients enter the study  under concomitant 
treatment with systemic antibiotics (as per protocol) on a stable dose (defined as a dose or 
dose regimen that has not changed in the previous [ADDRESS_37330] 16 weeks during the study ).
8.History  of hypersensitivity  to any  of the study  drug constituents.

[COMPANY_001] Confidentia l Page 34
Amended Protocol Version 02 ( Clean ) Protocol No. CAIN457M2301
9. Previous exposure to secukinumab (AIN457) or any other biologic drug directl y targeting 
IL-17 A/F or the IL -[ADDRESS_37331] two weeks (exception: common cold) prior to randomization.
11.Evidence of tuberculosis infection as defined by a positive QuantiFERON®TB-Gold test 
(QFT) at screening. Patients with a positive or indeterminate QFT test may participate in 
the study  if a full tuberculosis work -up (according to local practice/guidelines) completed 
within [ADDRESS_37332] of infection with human immunodeficiency virus (HIV), hepatitis B 
or C prior to randomization, except for hepatitis C successfull y treated and cured.
13.History  of ly mphoproliferative disease or any  known malignancy  or history  of malignancy 
of any organ system treated or untreated within the past 5 y ears, regardless of whet her there 
is evidence of local recurrence or metastases (except for skin Bowen’s disease, or basal cell 
carcinoma or actinic keratoses that have been treated with no evidence of recurrence in the 
past 12 weeks; carcinoma in situ of the cervix or non -invasi ve malignant colon poly ps that 
have been removed).
14.History  or evidence of ongoing alcohol or drug abuse, which in the opi[INVESTIGATOR_37196] .
15.Pregnant or lactating women.
16.Women of childbearing potential, defined as all women physiologically  capable of 
becoming pregnant, unless they  are using methods of contraception during the entire study 
or longer if required by [CONTACT_37232] (e.g. in European Union 
(EU) 20 weeks).
Contraception methods include:
Total abstinence, when this is in line with the preferred and usual lifest yle of the patient. 
Periodic abstinence (e.g. calendar, ovulation, sy mptothermal, post -ovulation methods) 
and withdrawal are not a cceptable methods of contraception.
Female sterilization (have had surgical bilateral oophorectom y with or without 
hysterectomy), total hysterectomy, or bilateral tubal ligation at least six weeks before 
taking study  treatment. In case of oophorectom y alone, only when the reproductive 
status of the woman has been confirmed b y follow -up hormone level assessment.
Male sterilization (at least 6 months prior to screeni ng). The vasectomized male partner 
should be the sole partner for that patient.
Barrier methods of contraception: Condom or Occlusive cap (diaphragm or 
cervical/vault caps). For [LOCATION_008]: with spermicidal 
foam/gel/film/cream/vaginal suppository .
Use of oral (estrogen and progesterone), injected or implanted hormonal methods of 
contraception or other forms of hormonal contraception that have comparable efficacy 
(failure rate <1%), for example hormone vaginal ring or transdermal hormone 
contraception orplacement of an intrauterine device (IUD) or intrauterine system (IUS).

[COMPANY_001] Confidentia l Page 35
Amended Protocol Version 02 ( Clean ) Protocol No. CAIN457M2301
In case of use of oral contraception, women should have been stable on the same pi[INVESTIGATOR_6522] a 
minimum of [ADDRESS_37333] y and will be described in the informed consent form (ICF).
Note: Women are considered post-menopausal and not of childbearing potential if they have 
had 12 months of natural (spontaneous) amenorr hea with an appropriate clinical profile (e.g. 
age appropriate, history  of vasomotor symptoms) or have had surgical bilateral 
oophorectom y (with or without hy sterectom y), total hysterectom y or bilateral tubal ligation 
at least six weeks prior to enrollment . In the case of oophorectom y alone, only when the 
reproductive status of the woman has been confirmed by [CONTACT_6492] -up hormone level 
assessment is she considered not of childbearing potential.
No additional exclusions may be applied by [CONTACT_093], in order to ensure that the study  
population will be representative of all eligible patients.
6 Treatment
6.1 Stud y treatment
6.1.1 Investigational and control drugs
Table 6-1 Investigational and control drug
Investigational/ 
Control Drug
(Name [CONTACT_6673])Pharmaceutical 
Dosage FormRoute of 
Administration Blinding/volumeSponsor (global or 
local)
Secukinumab [ADDRESS_37334] packs; 2 ml 
pre-filled syringeSponsor (global)
Placebo Solution for 
injectionSubcutaneous Use Double blinded 
subject packs; 2 ml 
pre-filled syringeSponsor (global)
[COMPANY_001] will supply  the investigational therapy  as follows:
Secukinumab 300 mg solution for sub-cutaneous injection in a 2 ml pre- filled sy ringe
Placebo solution for sub -cutaneous injection in a 2 ml pre-filled s yringe
Each placebo pre-filled syringe contains a mixture of inactive excipi[INVESTIGATOR_840], matching the 
composition and the appearan ce of the secukinumab 300 mg dose.
Secukinumab and the secukinumab matching placebo will be labeled as “AIN457 300 mg / 
Placebo” (2 ml) to keep the blind. Subjects will be initially  instructed about injections by [CONTACT_37233]. They  will also receive instruct ions on how to self -inject using the pre -filled sy ringe.
6.1.2 Additional study treatments
No additional treatment bey ond investigational drug and control drug are included in this trial. 
Subjects are requested to use over-the-counter antiseptics according to eligibility 
criteria, Section 6.2.1 and Section 6.2.2 . For rescue medication, see Section 6.2.3 .

[COMPANY_001] Confidentia l Page 36
Amended Protocol Version 02 ( Clean ) Protocol No. CAIN457M2301
6.1.3 Treatment arms/group
At Baseline/Randomization visit, all eligible subjects will be randomized via Interactive 
Response Technology  (IRT) in a 1:1:0.5:0.5 ratio to one of the following 4 treatment groups:
• Secukinumab 300 mg every 2 weeks group: subjects will receive a loading dose of 
secukinumab 300 mg once weekl y for four weeks (at Randomization, Weeks 1, 2, 3 and 4), 
followed by [CONTACT_37234] 300 mg every  two weeks, starting at Week 6 and up to Week 50. 
These subjects will receive two additional placebo injections at Weeks 17 and 19to maintain 
the treatment blind during the re -induction.
• Secukinumab 300 mg every 4 weeks group: subjects will receive secukinumab 300 mg once 
weekl y for four weeks (at Randomization, Weeks 1, 2, 3 and 4), followed by [CONTACT_37234] 300 
mg every  four weeks, starting at Week 8 and up to W eek 48. In order to maintain the treatment 
blind, subjects in this group will also receive a placebo injection every  4 weeks starting at Week 
6, until Week 50. These subjects will receive three additional placebo injections at Weeks 17, 
18 and 19 to mainta in the treatment blind during the re -induction.
• Placebo group to secukinumab 300 mg every 2 weeks: subjects will receive placebo once 
weekl y for four weeks (at Randomization, Weeks 1, 2, 3 and 4), followed by [CONTACT_37235], starting at Week 6 and up to Week 14. At Week 16, subjects will be switched from 
Placebo to Secukinumab 300 mg every 2 weeks. The subjects will receive secukinumab 300 
mg once weekl y for four weeks (Weeks 16, 17, 18, 19 and 20), followed by [CONTACT_37234] 300 
mg every  two weeks, starting at Week 22 and until Week 50.
• Placebo group to secukinumab 300 mg every 4 weeks: subjects will receive placebo once 
weekl y for four weeks (at Randomization, Weeks 1, 2, 3 and 4), followed by [CONTACT_37235], starting at Week 6 and up toWeek 14. At Week 16, subjects will be switched from 
Placebo to Secukinumab 300 mg every 4 weeks. The subjects will receive secukinumab 300 
mg once weekl y for four weeks (Weeks 16, 17, 18, 19 and 20), followed by [CONTACT_37234] [ADDRESS_37335] -treatment Follow -up in this study .
6.2 Other treatment(s)
6.2.[ADDRESS_37336] to notify  the study  site about any new medications 
taken after enrolling in the study . All medications, procedures and significant non-drug 
therapi[INVESTIGATOR_014] (including physical therap y and blood transfusions) administered after the subject was 

[COMPANY_001] Confidentia l Page 37
Amended Protocol Version 02 ( Clean ) Protocol No. CAIN457M2301
enrolled into the study  must be recorded on the appropriate electronic case report/record form
(eCRF ).
Each concomitant drug must be individually  assessed against all exclusion criteria/prohibited 
medication. If in doubt, the investigator should contact [CONTACT_18614] a subject or allowing a new medication to be started.
[IP_ADDRESS] Permitted concomitant therapy
Antiseptic Therapy
Subjects should be instructed to use dail y topi[INVESTIGATOR_37184] -the-counter antiseptics on the skin areas 
affecte d by [CONTACT_37236].
Wound Care
Concomitant use of wound care dressings on HS wounds is allowed following the local standard 
practice.
[IP_ADDRESS] Permitted concomitant therapy  requiring caution and/or action
Antibiotics
Systemic antibiotics for the treatment of acute systemic infectious disease both related or 
unrelated to HS (e.g. pneumonia, cellulitis) are allowed as medically  warranted during the study .
Systemic antibiotics for the treatment of HS are only allowed as rescue medica tion as described 
inSection 6.2.3 below.
For subjects entering the study  in the antibiotic strata, treatment with the following tetracy clines 
on a stable dose is allowed in Treatment Period 1:
Tetracy cline up to 500 mg twi ce a day
Minocy cline up to 100 mg twice a day
Doxycycline up to 100 mg twice a day
Analgesics
Subjects will be required to wash out opi[INVESTIGATOR_2467] (including tramadol) for 14 days prior 
to Baseline. This includes opi[INVESTIGATOR_37197] -related pain and non- HS-related pain.
Subjects on a stable dose of a non -opi[INVESTIGATOR_11595] ("as needed" is not considered stable) may  
continue the analgesic, provided the dose is stable for [ADDRESS_37337] presents with uncontrolled pain related to HS during the study, 
ibuprofen and acetaminophen (paracetamol) are permitted. 
If HS-related pain is uncontrolled with ibuprofen or acetaminophen (paracetamol) at the 
maximal dose as p er local label during the trial , subjects can be prescribed tramadol (at a dose 
of up to 100 mg orally  every  4 hours), not to exceed 400 mg/24 hours.

[COMPANY_001] Confidentia l Page 38
Amended Protocol Version 02 ( Clean ) Protocol No. CAIN457M2301
Information on the concomitant use of analgesics should be recorded by [CONTACT_37237] b y the investigator at the scheduled visits.
6.2.[ADDRESS_37338] 
to notify the study  site about any new treatments 
he/she takes after the start of study  treatment. All prohibited medications and significant non-
drug therapi[INVESTIGATOR_37198].
If a prohibited t reatment listed inTable 6-2is used during the study , the subject should 
discontinue use of the prohibited treatment if he/she wishes to continue in the study . At the 
discretion of the investigator, if the subject’s use during the study  of a prohibited treatment 
presents undue safety  risk for the subject, the subject should be discontinued from study 
treatment.
Table 6-
[ADDRESS_37339] dose of study  drug Action taken
Prior treatment with 
secukinumab or other 
agents blocking IL -17 A/F 
or IL-17RNot allowed Not allowed Subject not eligible
Systemic biological 
immunomodulating 
treatment (e.g. 
adalimumab, infliximab, 
ustekinumab, anakinra, 
natalizumab)12 weeks wash -out 
period or 5 half -
lives, whichever is 
longerNot allowed Discontinue use or 
discontinue study 
treatment
Systemic non -biologic 
immunomodulating 
treatment (e.g. 
methotrexate (MTX), 
cyclosporine A, retinoids, 
apremilast)28 days wash -out 
period requiredNot allowed Discontinue use or 
discontinue study 
treatment
Topi[INVESTIGATOR_37199]14 days wash -out 
period requiredNot allowed until W eek 16 Discontinue use or 
discontinue study 
treatment if not medically 
warranted
Antibiotics for the 
treatment of HS (non-
antibiotic strata)28 days wash -out 
period requiredNot allowed until W eek 16, 
except for rescue treatmentDiscontinue use or 
discontinue study 
treatment if not medically 
warranted
Systemic corticosteroids 
for the treatment of HS28 days wash -out 
period requiredNot allowed Discontinue use of 
discontinue study 
treatment

[COMPANY_001] Confidentia l Page 39
Amended Protocol Version 02 ( Clean ) Protocol No. CAIN457M2301
MedicationPrior to 
randomizationUse between randomization 
and last dose of study  drug Action taken
Opi[INVESTIGATOR_2467] 14 days wash -out 
period requiredNot allowed Discontinue use or 
discontinue study 
treatment
Surgeries for the 
treatment of HS other 
than allowed as rescue 
therapyNot allowed within 6 
weeks prior to 
randomizationNot allowed until W eek 16 Discontinue study 
treatment
Live vaccines Not a llowed within 6 
weeks prior to 
randomizationNot allowed Discontinue study 
treatment
Any investigational 
treatment or participation 
in any interventional trial28 days or 5 half -
lives (whichever is 
longer) wash -out 
period requiredNot allowed Discontinue study 
treatment
6.2.[ADDRESS_37340] experiences an increase in their AN count (for example, the 
total count is greater- than-or-equal -to 150% of the weighted average of screening and baseline 
AN count (Section 12.4.1 ))with a minimum increase of [ADDRESS_37341] remain stable until Week 16. Except 
for current antibiotic use strata, concomitant use of antibiotic therapy  for treatment of HS is 
otherwise not allowed. However, antibiotics are permi tted to treat an acute infection if 
medically  warranted (Section [IP_ADDRESS] ).Rescue antibiotic therapy  should be captured in the 
source and on the appropriate eCRF.
Lesion Intervention
In the event of an acutely  painful single lesion that requires an immediate intervention, the 
investigator will be allowed toperform an unplanned surgery /intervention for lesion such as 
excision, drainage or intra -lesion steroid administration at any  time.
Other HS related surgery is not allo wed until after Week 16.
All study  visit evaluations must take place before any interventions are performed.
6.[ADDRESS_37342] Number (Subject No.) that is assigned when 
the patient is enrolled for screening and is retained for the subject throughout his/her 
participation in the trial. A new Subject No.will be assigned if the subject is rescreened. The 
Subject No. consists of the Center Number (Center No.) (as assigned by [CONTACT_37238]) with a sequential subject number suffixed to it, so that each subject

[COMPANY_001] Confidentia l Page 40
Amended Protocol Version 02 ( Clean ) Protocol No. CAIN457M2301
participation is numbered uniquely  across the entire database. Upon signing the informed 
consent form, the patient is assigned to the next sequential Subject No. available within the 
electronic data capture (EDC) system. 
The investigator or his/her staff will contact [CONTACT_37239] I RT.
If the subject fails to be treated for any  reason, the IRT must be notified within [ADDRESS_37343] was not treated. The reason for not being treated will be entered on the appropriate 
eCRF.
6.3.2 Treatment assignment, randomization
The investigator or his/h er delegate will contact [CONTACT_37240]/exclusion criteria. The IRT will assign a randomization number to the subject, 
which will be used to link the subject to a treatment arm and will specify  a unique medication 
number for the package of study  drug to be dispensed to the subject. The randomization number 
will not be communicated to the investigator or his/her delegate.
The randomization numbers will be generated using the following procedure to ensure that 
treatment assignment is unbiased and concealed from subjects and investigator staff. A patient 
randomization list will be produced by [CONTACT_6609] a validated system that automates 
the random assignment of patient numbers to randomization numbers. These randomization 
numbers are linked to the different treatment arms, which in turn are linked to medication 
numbers. A separate medication list will be produced by [CONTACT_37241] a validated system that automates the random assignment of 
medication numbers to packs containing the investigational drug(s).
Randomization will be stratified by [CONTACT_11338], concomitant antibiotic use (Yes/No) and body 
weight (weight < 90kg / ≥ 90kg).
The randomization scheme for subjects will be reviewed and approved by a m ember of the 
Randomization Group.
6.4 Treatment blinding
This is a double blind study . Subjects, investigator staff, persons performing the assessments, 
and [COMPANY_001] Clinical Trial Team (CTT) will remain blind to the identity  of the treatment from 
the time of randomization until database lock, using the following methods:
1. Randomization data are kept strictl y confidential until the time of unblinding, and will not be 
accessible by  [CONTACT_37242]:
Specific vendors whose role in trial conduct requires their unblinding (e.g., IRT)
Drug Supply  Management
The designated [COMPANY_001] study  team members involved in the primary  endpoint analy sis
2. The identity  of the treatments will be concealed by [CONTACT_37243], labeling, schedule of administration, appearance and schedule of 
administration.

[COMPANY_001] Confidentia l Page 41
Amended Protocol Version 02 ( Clean ) Protocol No. CAIN457M2301
The randomization codes associated with subjects from whom PK samples are taken will be 
disclosed to the bioanal yst and pharmacokineticist (if required at primary  endpoint analysis) 
who will keep serum concentrations confidential until database lock.
For subjects, investigators/site personnel and [COMPANY_001] personnel working directly  with the sites, 
unblinding will occur in the case of subject emergencies (see Section 6.6.3 ), and at the 
conclusion of the study. The appropriate personnel from the study  site and [COMPANY_001] will assess 
whether the study  treatment should be discontinued for any subject whose treatment code has 
been broken inadvertently for an y reason.
At the time of a primary endpoint analysis after all subjects have completed Week 16, the 
designated [COMPANY_001] personnel (e.g. biostatisticians and programmers involved in the analy sis, 
key Global Team members) may have access to the unblinded results. Field monitors/clinical 
research associates will remain blinded until after final database lock. Subjects and site 
personnel directly  involved in the conduct of the trial, i.e. investigator staff and persons 
performing the assessments, will remain blinded to individual treatment allocation until the 
conclusion of the study  to ensure study  integrit y is maintained.
6.5 Dose escalation and dose modification
Investigational or other study  treatment dose adjustments and/or interruptions are not permitted.
6.5.[ADDRESS_37344] eCRF page (visit specific and summary  pages). For study  treatment 
administration at home, the investigator must promote compliance b y instructing t he subject to 
administer the stud y treatment exactly  as instructed and b y stating that compliance is necessary 
for the subject’s safet y and the validity  of the study . The subject must also be instructed to 
contact [CONTACT_087]/she is unable for any reason to administer the study  treatment. 
Compliance will be assessed by [CONTACT_1755]/or study  personnel at each visit using empty 
medication packaging, pre-filled syringe (PFS) and information provided by [CONTACT_423]. This 
information should becaptured in the source document at each visit. All study  treatment 
dispensed and returned must be recorded in the Drug Accountabilit y Log. Compliance will also 

[COMPANY_001] Confidentia l Page 42
Amended Protocol Version 02 ( Clean ) Protocol No. CAIN457M2301
be assessed and confirmed by a field monitor by [CONTACT_37244], by [CONTACT_37245], administration and accountability . Cross -checks should be performed 
for home administrations (H) and empty  medication outer packing and patient' s returned PFS 
should be collected for compliance checks b y field monitors.
Pharmacokinetic parameters (measures of treatment exposure) will be determined in all subjects 
treated with secukinumab, as detailed in the Pharmacokinetics Section 8.5.[ADDRESS_37345] -of-care andis at the 
discretion of the investigator or treating physician. There are no specific treatment 
recommendations for adverse events that may possibly  occur in this trial. Refer to the 
Investigator's Brochure for adverse events related to secukinumab.
6.6.[ADDRESS_37346], he/she must provide the 
requested subject identifying information and confirm the necessit y to break the treatment code 
for the subject. Theinvestigator will then receive details of the investigational drug treatment 
for the specified subject and a fax or email confirming this information. The system will 
automatically  inform the [COMPANY_001] monitor for the site and the study  team that the code has been 
broken.
It is the investigator’s responsibility  to ensure that there is a dependable procedure in place to 
allow access to the IRT at any  time in case of emergency . The investigator will provide:
protocol number
study  drug name (if available)
subject number
In addition, oral and written information to the subject must be provided on how to contact [CONTACT_1275]'s backup in cases of emergency , or when he/she is unavailable, to ensure that un-
blinding can be performed at an y time.
Study  treatment must be discontinued after emergency  unblinding.
6.[ADDRESS_37347] by [CONTACT_37246](s). The study medication has a 2 -part label (base 
plus tear-off label), immediately  before dispensing the medication kit to the subject, site 
personnel will detach the outer part of the label from the packaging and affix it to the source 
document.

[COMPANY_001] Confidentia l Page 43
Amended Protocol Version 02 ( Clean ) Protocol No. CAIN457M2301
In case of a major health care  event (e.g., pandemic, epi[INVESTIGATOR_901]) thatlimits or prevents on-site 
study  visits, if required alternative way s to provide study  drug may be implemented, including 
but not limited to shippi[INVESTIGATOR_37200]. The 
shipment/provisioning should cover an adequate period, based on local situation and 
regulations. In thiscase, regular phone calls or virtual contacts (approximately  every 4 weeks, 
prior to home administration, or more frequentl y if needed) will occur between the site and the 
subject forinstructional purposes, safety  monitoring and discussion on patient’s health status 
until the subject can again visit the site.
This is necessary  to ensure that there are no safety  concerns to the subject requiring treatment 
interruption or discontinuation.
The subjects will be supplied with material to document drug self-administration andtoallow 
accountability  of thestudy  medication. At the site level, the agreement with/approval of the 
Principal Investigator, Ethics Committee/ Institutional Review Board (EC/IRB) and anyother 
Board as appropriate should be in place to implement home delivery .
6.7.1 Handling of study treatment and additional treatment
[IP_ADDRESS] Handling of study  treatment
Study  treatment must be received by a designated person at the study  site, handled and stored 
safel y and properl y and kept in a secured location to which only the investigator and designated 
site personnel have access. Upon receipt, all study  treatment must be stored according to the 
instructions specified on the labels. Clinical supplies are to be dispensed only in accordance 
with the protocol. Technical complaints are to be reported to the respective [COMPANY_001] Country 
Organization (CO) Quality  Assurance.
Medication labels will be in the local language and comply with the legal requ irements of each 
country . They  will include storage conditions for the study  treatment but no information about 
the subject except for the medication number .
The investigator must maintain an accurate record of the shipment and dispensing of study 
treatment in a drug accountability  log. Monitoring of drug accountability  will be performed by 
[CONTACT_18609]. The subjects will record 
the date(s) of administration at home on a diary  and will return theused medication and 
packaging at their next visit to the site. Site staff will record in the appropriate documents the 
dates of the administration. Detailed instructions will be provided separately . Subjects will be 
asked to return all unused study  treatm ent and packaging at the end of the study  or at the time 
of discontinuation of study treatment.
At the conclusion of the study , and as appropriate during the course of the study , the investigator 
will return all unused study  treatment, packaging, drug labels, and a copy of the completed drug 
accountability  log to the [COMPANY_001] monitor or to the [COMPANY_001] address provided in the investigator 
folder at each site.
[IP_ADDRESS] Handling of additional treatment
Not applicable.

[COMPANY_001] Confidentia l Page 44
Amended Protocol Version 02 ( Clean ) Protocol No. CAIN457M2301
6.7.2 Instruction for prescribing and taking study treat ment
Secukinumab solution for s.c. injection or placebo secukinumab solution (active or placebo, 
respectivel y) will be provided in pre -filled s yringes (PFS).
Each subject will require one box with PFS per dose throughout the stud y:
One secukinumab 300 mg, 2ml PFS OR
One secukinumab placebo [ADDRESS_37348] study  treatment administration will occur at the baseline/randomization visit after the 
inclusion/exclusion criteria have been confirmed and all study  scheduled assessments have been 
performed. All study assessments, including completion of Patient Reported Outcomes (PROs) 
and blood withdrawal, should be completed prior to the self- inject ion of study  treatment.
All doses of study  treatment (secukinumab and/or placebo) will be self-administered by [CONTACT_1560]/ trained caregiver either at the study  site after the study  assessments for the visits have 
been completed or at home.
The first use at baseline and the Week [ADDRESS_37349] via the pre -filled 
syringe (Instructions for Use (IFU) containing detailed information about self-administration of 
study  treatment should be provided to each subject at the beginning of the study ). After 
providing detailed explanations/instructions, subj ects will then be asked to raise an y questions. 
Thereafter, they will proceed with self-injection. At Week 1, subjects will be asked to refer to 
the IFU and to proceed with self-injection of the actual study  drug (i.e. without a detailed 
explanation/instru ction on handling the s yringe).
Home administrations (H) should be done at pre-defined visits (see Section 3 ). Home 
administration can be performed by  [CONTACT_37247]. If the subject or caregiver 
is not able/confident to perform home administration, the subject will be allowed to return to 
the site for administration of the medication. However, during those visits no additional 
assessments will be required.
During home administrations, subjects will be in structed to contact [CONTACT_093]/site staff in 
case they  are experiencing any  AE/SAEs or have any  concerns.
In case of a major health care event (e.g., pandemic, epi[INVESTIGATOR_901]) that limits or prevents on-site 
study  visits, home administration of the study  drug could be generally permitted. Home 
administration can be performed by [CONTACT_37248] a trained caregiver. Study  participants or 
caregivers will be trained adequatel y on how to perform administrations of the study treatment, 
if not already trained. If thesubject or caregiver is not trained for drug administration and 
cannot visit the site to undergo training, the site can consider providing suitable virtual training 
and oversight. A joint decision together with thesubject or caregiver should be made asto 
whether this constitutes sufficient training and oversight.

[COMPANY_001] Confidentia l Page 45
Amended Protocol Version 02 ( Clean ) Protocol No. CAIN457M2301
Administration
The study  treatment solution must be injected in non -affected areas of the skin.
Pre-filled syringes should be kept at 2 to 8°C (36°F and 46°F), never be frozen, and should be 
protected from light. Prior to administration, the boxes containing the pre-filled syringes should 
be allowed to adapt to room temperature unopened for about 30 to 45 minutes before 
administration. Used PFS (if according to the regulatory  needs of the respective countries) 
should be stored in the original boxes and returned at the next site visit for reconciliation.
7 Informed consent procedures
Eligible subjects may  only  be included in the study  after providing (witnessed, where required 
by [CONTACT_6617] ), IRB/IEC -approved informed consent.
If applicable, in cases where the subject's representative(s) gives consent (if allowed according 
to local requirements), the subject must be informed about the study  to the extent possible given 
his/her understanding. If the subject is capable of doing so, he/she must indicate agreement by 
[CONTACT_37249] y signing and dating the written informed consent document.
Informed consent must be obtained before conducting any study-specific procedures (e.g. all of 
the procedures described in the protocol). The process of obtaining informed consent must be 
documented in the subject source documents.
[COMPANY_001] will provide to investigators in a separate document a proposed informed consent form 
that complies with the ICH GCP guidelines and regulatory  requirements and is considered 
appropriate for this study . Any changes to the proposed consent form suggested by [CONTACT_37250]/IEC and a copy of the 
approved version must be provided to the [COMPANY_001] monitor after IRB/ IEC approval.
Information about common side effects alread y known about the investigational drug can be 
found in the Investigator's Brochure (IB) and CDS. This information will be included in the 
subject informed consent and should be discussed with the subject during the study  as needed. 
Any new information regarding the safet y profile of the investigational drug that is identified 
between IB updates will be communicated as appropriate, for example, via an investigator 
notification or an aggregate safet y finding. New information might require an update to the 
informed consent and then must be discussed with the subject.
Women of child bearing potential must be informed that taking the study  treatment may involve 
unknown risks to the fetus if pregnancy  were to occur during the study  and agree that in order 
to participate in the study  they must adhere to the contraception requirements for the duration 
of the study . If there is any  question that the subject will not reliably  comply , they  must not be 
entered in the stud y.
The study  includes optional sub-study  (biops y sampling) / DNA component which requires a 
separate signature [CONTACT_37309]. It is required as part of this protocol that 
the Investigator presents this option to the subjects, as permitted by [CONTACT_37251]. 
The process for obtaining consent should be exactly  the same as described above for the main 
informed consent.

[COMPANY_001] Confidentia l Page 46
Amended Protocol Version 02 ( Clean ) Protocol No. CAIN457M2301
Declining to participate in these optional assessments (DNA / biops y sampling substudy ) will 
in no way affect the subject’s ability  to participate in the main research study .
A copy of the approved version of all consent forms must be provided to [COMPANY_001] after IRB/IEC 
approval.
Subjects might be asked to complete an optional questionnaire to provide feedback on their 
clinical trial experience.
During a major health care disruption (e.g., pandemic, epi[INVESTIGATOR_901]) that may challenge the ability 
to obtain a standard written informed consent due to limits that prevent an on-site visit, the 
Investigator may conduct the informed consent discussion remotely  (e.g. telephone, 
videoconference). Guidance issued by [CONTACT_37252] y documented (e.g. the presence of an impartial witness, 
sign/dating separate ICFs by  [CONTACT_37253], etc).
8 Visit schedule and assessments
Table 8-1lists all of the study visits and indicates with an “X” when the assessments are to be 
performed. An ‘S’ indicates the data for that assessment are in the source documents at the site.
Subjects should be seen for all visits on the designated day or as close as possible to the original 
planned visit schedule.
If for an y reason the s ubject is a screen failure, the subject may  be rescreened once onl y.
If a subject rescreens for the study , then the subject must sign a new ICF and be issued a new 
subject number prior to any screening assessment being conducted for the subject under the 
new screening subject number. For all rescreened subjects, the investigator/qualified site staff 
will record if the subject was rescreened on the rescreening eCRF and the original screenin g 
number the subject was issued prior to the current screening number .
Informed Consent for a rescreened subject must be obtained prior to performing any study -
related assessment or collecting an y dat a for the Screening Visit. For rescreening, all screening 
assessments must be performed as per protocol, except for the tuberculosis (TB) work up, if 
applicable, if performed not more than [ADDRESS_37350] performed b y the central laboratory.
During the treatment periods, subjects may be seen at an unscheduled visit, e.g., if they 
experience deterioration of HS, or AEs that in the opi[INVESTIGATOR_37201]. The assessment(s) performed at an unscheduled visit are at the 
investigator’s discretion.
Subjects who discontinue study  treatment will continue to be followed up for as long as possible, 
and efforts should be made so that subjects continue study visits as per the assessment schedule 
even if not on study  drug. Special effort should be made up u ntil Week 16 to ensure that those 
subjects who prematurely  discontinue study  treatment attend all scheduled visits.
Subjects who discontinue study  treatment before completing the study  and do not wish to attend 
site visits for assessments only  should be scheduled for an end of study visit 2 weeks (wherever 
possible) after their last study treatment administration, at which time all the assessments listed 

[COMPANY_001] Confidentia l Page 47
Amended Protocol Version 02 ( Clean ) Protocol No. CAIN457M2301
for EOT 1 (Week 16)/EOT 2 (Week 52) will be performed. Subjects should then return to the 
study  site [ADDRESS_37351] them or a knowledgeable informant by [CONTACT_37254] (i.e. certified letter) immediatel y. At this contact, the safety  (e.g., potential 
occurrence of AE or SAE) and the primary reason for a subject’s premature withdrawal should 
be determined.
At a minimum, subjects who pre-maturel y discontinue the treatment will be contact[CONTACT_15025] y 
evaluations during the [ADDRESS_37352].
It is recommended that assessments be completed in the following order: PROs, Physician 
assessments, study  visit procedures (e.g. laboratory  and PK sample collection, vital signs 
measurements), stud y treatment administra tion.
In the event of a major health care event (e.g., pandemic, epi[INVESTIGATOR_901]) that limits or prevents on -
site study  visits, regular phone calls (approximately  every 4 weeks or more frequentl y, if needed) 
will occur until the subject can again visit the site. Events qualify ing for being reported in the 
case report form (e.g., AE, procedure) should be entered as appropriate. Special effort should 
be made to collect information related to EOT 1, (Week 16) and EOT 2 (Week 52) visits. If it 
is not feasible to condu ct these visits on-site, phone calls should be attempted instead. 
Additional Unscheduled doses could be given at Home after Week [ADDRESS_37353] is able to perform the Week 52 visit on -site.

[COMPANY_001] Confidential Page 48
Amended Protocol Version 02 (Clean ) Protocol No. CAIN457M2301
Table 8-[ADDRESS_37354] -Treatment 
Follow -Up
Visit Name
[CONTACT_6674] 
1
Screening 
2
Baseline
Week 1
Week 2Week 3Week 4
Week 8
Week 12
Week 16 / 
EOT1
Week 17
Week 18 Week 19 Week 20 Week 24 Week 28 Week 32
Week 36
Week 40 Week 44 Week 48
UNS 1 to 3
Week 52 /
EOT2Week 60 / F8
Days -28 to -14 -13 to -1 1 8 15 22 29 57 85 113 120 127 134 141 169 197 225 253 281 309 337 365 421
Obtain informed 
consent (ICF)X
Demography X
Inclusion / Exclusion 
criteria1X X X
Washout evaluation / 
instructionS S S
Relevant medical 
history / current 
medical conditionX
HS medical history 
and previous therapi[INVESTIGATOR_014] X
Smoking history X
Hurley stage X X X X X
Prior / concomitant 
medications2X Update as necessary
Adverse Events3X Update as necessary
Physical Examination1S S S S
Body Height X
Body W eight X X X X X X
Vital Signs X X X X X X X X X X X X X X X X
Tuberculosis test X X

[COMPANY_001] Confidential Page 49
Amended Protocol Version 02 (Clean ) Protocol No. CAIN457M2301
Period Screening Treatment Period [ADDRESS_37355] -Treatment 
Follow -Up
Visit Name
[CONTACT_6674] 
1
Screening 
2
Baseline
Week 1
Week 2Week 3Week 4
Week 8
Week 12
Week 16 / 
EOT1
Week 17
Week 18 Week 19 Week 20 Week 24 Week 28 Week 32
Week 36
Week 40 Week 44 Week 48
UNS 1 to 3
Week 52 /
EOT2Week 60 / F8
Days -28 to -14 -13 to -1 1 8 15 22 29 57 85 113 120 127 134 141 169 197 225 253 281 309 337 365 421
Lesion count 
(physician)X X X X X X X X X X X X X X X X X X X
Flare assessment4X X X X X X X X X X X X X X X X X X X
Numerical Rating 
Scale for pain 
assessment5Completed daily in the eDiary Completed weekly in the eDiary
Modified Hidradenitis 
Suppurativa Score 
(mHSS)X X X X
HS-Physician's Global 
AssessmentX X X X X X X X
Patient's Lesion Count Completed weekly in the eDiary
DLQI X X X X X X X
EQ5D X X X X X X X
Patient Global 
Impression of severity 
(PGI-s)X X X X X X X
Patient Global 
Impression of change 
(PGI-c)X X X X X X X
Work productivity 
Activity Impairment 
(WPAI)X X X X X X
HS Symptom Diary6Completed daily in the eDiary X X X X X
Hematology X X X X X X X X X X X X X

[COMPANY_001] Confidential Page 50
Amended Protocol Version 02 (Clean ) Protocol No. CAIN457M2301
Period Screening Treatment Period [ADDRESS_37356] -Treatment 
Follow -Up
Visit Name
[CONTACT_6674] 
1
Screening 
2
Baseline
Week 1
Week 2Week 3Week 4
Week 8
Week 12
Week 16 / 
EOT1
Week 17
Week 18 Week 19 Week 20 Week 24 Week 28 Week 32
Week 36
Week 40 Week 44 Week 48
UNS 1 to 3
Week 52 /
EOT2Week 60 / F8
Days -[ADDRESS_37357] IRT S S S S S S S S S S S S S S S S S S S S S S
Randomization X
Drug dispensation9X X X X X X X X X X X X X X X X X X X X
Dose administration10X X X X X X X X X X X X X X X X X X X X
Period 
completion/disposition 
formX X X
Health care resource 
utilizationX X X X X

[COMPANY_001] Confidential Page 51
Amended Protocol Version 02 (Clean ) Protocol No. CAIN457M2301
Period Screening Treatment Period [ADDRESS_37358] -Treatment 
Follow -Up
Visit Name
[CONTACT_6674] 
1
Screening 
2
Baseline
Week 1
Week 2Week 3Week 4
Week 8
Week 12
Week 16 / 
EOT1
Week 17
Week 18 Week 19 Week 20 Week 24 Week 28 Week 32
Week 36
Week 40 Week 44 Week 48
UNS 1 to 3
Week 52 /
EOT2Week 60 / F8
Days -28 to -14 -13 to -1 1 8 15 22 29 57 85 113 120 127 134 141 169 197 225 253 281 309 337 365 421
Trial Feedback 
Questionnaire 
(optional)X X X
XAssessment to be recorded in the clinical database or received electronically from a vendor
SAssessment to be recorded in the source documentation only
1These assessments are source documentation only and will not be entered i nto the eCRF. However, data regarding to which inclusion/exclusion criteria are not met are 
captured on the Inclusion/Exclusion eCRF.
2While all concomitant medications are recorded on eCRF, patients will record their daily analgesics use on eDiary. 
3AEs /SAEs occurring after the patient has provided informed consent must be reported.
4Occurrence of flare will be calculated from lesion count assessment and does not require any additional action from the site staff.
5Subjects will complete the NRS skin pain assessment using eDiary. From Screening through W eek 16, subjects will complete a daily diary of their skin pain. From W eek [ADDRESS_37359] or caregiver is not able/confident to perform 
home administration, the subject will be allowed to return to the site for administration of the medication. 

[COMPANY_001] Confidential Page 52
Amended Protocol Version 02 (Clean ) Protocol No. CAIN457M2301
8.[ADDRESS_37360] be notified within 5 days and the 
reason for not being randomized will be entered on the disposition eCRF. In addition, the 
Screening visit date, the Demograph y eCRF, Informed Consent eCRF, Inclusion/Exclusion 
Criteria eCRF and Subject rescreening eCRF (for rescreened subjects) must be completed.
Adverse events that are not SAEs will be fol lowed up by  [CONTACT_37255] y in 
the source data. However, serious adverse events should be recorded in the eCRF for any serious 
adverse event (SAEs) that occurred during the screening period. If consent was withdrawn 
during the screening period before the subject was randomized, complete the appropriate eCRF.
8.[ADDRESS_37361] demographics/other baseline characteristics
8.2.[ADDRESS_37362] demographics data will include: age, gender, race, and ethnicity.
8.2.2 HS medical history /diagnosis
The following information should be collected and entered in the relevant eCRF:
The date of first sy mptoms
The date of first diagnosis of HS
HS family  history
8.2.3 Prior HS medications and therapy
Any treatments for HS since initial diagnosis (as determined through medical history  records 
or through subject interview) prior to study  entry will be collected and recorded in the eCRF 
(including previous use of antibiotics, non-biologic immunomodulators and biologic therapi[INVESTIGATOR_014]), 
along with the duration of the prior therap y and the reason for discontinuation.
8.2.[ADDRESS_37363] scarring, 
ranging from isolated abscesses in the primary  stage to coalescing lesions with scarring and 
sinus tracts in the tertiary stage ( Table 8 -2). Hurley  stage will be recorded in eCRF.
Table 8-2 Hurley  stages
Stage Description
I Abscess formation, single or multiple without sinus tracts and cicatrization/scarring
II Recurrent abscesses with tract formation and cicatrization. Single or multiple, widely separated 
lesions

[COMPANY_001] Confidential Page 53
Amended Protocol Version 02 (Clean ) Protocol No. CAIN457M2301
Stage Description
III Diffuse or near-diffuse involvement, or multiple interconnected tracts and abscesses across entire 
area
8.2.5 Smoking History
The current and/or previous use of tobacco use will be recorded prior to randomization, as well 
as the estimated number of pack -years based on the approximate consumption per y ear.
8.2.6 Relevant medical history /current medica l conditions
Relevant medical history and current medical conditions includes data prior to signing of the 
informed consent and should be recorded in the Medical History  eCRF. Whenever possible, 
diagnoses and not s ymptoms should be recorded.
Significant findings that are observed after the subject has signed the ICF and that meet the 
definition of an AE must be recorded in the AE eCRF.
8.2.[ADDRESS_37364] in the eDiary and reviewed by [CONTACT_37256].
8.2.8 Determination of the tuberculosis status
Determination of the tuberculosis (TB) status should be done at Screening and should be 
performed as defined by [CONTACT_13144]. The TB status must be determined by [CONTACT_9870] , 
signs, symptoms, TB testing (QuantiFERON -TB Gold assay ). Any significant findings should 
be recorded in the eCRF.
QuantiFERON TB -Gold In -Tube assay
A QuantiFERON®TB-Gold In- Tube assay (QFT) to screen a population for latent tuberculosis 
infection ( Dohert yet al 2008 ) will be used at Screening to evaluate the subjects’ eligibility  for 
the study . This blood -based assay  is specific for Mycobacterium tuberculosis and is not 
influenced by [CONTACT_37257] -Guér in vaccination or by [CONTACT_37258]. Furthermore, this test, in contrast to the purified protein derivative ([COMPANY_003]) 
skin test, is also insensitive to a booster effect since the subject is not exposed to the vaccine. 
The assay  measures the production of interferon- gamma and presents it relative to a negative 
and a positive control sample ( Manuel andKumar 2008 ). The QuantiFERON®-TB Gold assay 
test will be supplied by [CONTACT_2237] . Details on the collection, shipment of samples 
and reporting of results by [CONTACT_37259] -
specific Laboratory  Manual.
The workflow of sample handling in case of positive or indeterminate test results is provided in
Figure 8 -1.
If the test result is negative , the subject may  be randomized.

[COMPANY_001] Confidential Page 54
Amended Protocol Version 02 (Clean ) Protocol No. CAIN457M2301
If the test result is positive , the investigator should perform a work -up for the test result as 
per local procedures. If a TB work -up was conducted prior to the screening of the subject, 
results of the work- up can be used to assess eligibility  if the work- up was conducted 
within 12 weeks prior to randomization. 
Subjects positive for latent TB per work -up may  be randomized to the trial if 
sufficient treatment has been initiated according to local routine clinical practice and 
completed at least four weeks before randomization .
Subjects positive for active TB per work -up are not eli gible for the study .
Subjects negative for TB (no signs of latent or active TB) per work -up may  be 
randomized to the trial.
If the test result is indeterminate , the investigator may repeat the test once or may 
proceed directly to perform the work -up for the test result as per local procedures. This 
action is at the discretion of the investigator. If a TB work -up was conducted prior to the 
screening of the subject, results of the work -up can be used to assess eligibility  if the 
work -up was conducted within 1 2 weeks prior to randomization. 
If the second test is negative, the subject may  be randomized.
If the second test is positive, the investigator should perform work -up as per local 
guidelines. Subjects positive for latent TB per work -up may  be randomized t o the 
trial if sufficient treatment has been initiated according to local routine clinical 
practice and completed at least four weeks before randomization . Subjects positive 
for active TB per work -up are not eligible for the study . Subjects negative for TB (no 
signs of latent or active TB) per work -up may  be randomized to the trial.
If the second test is again indeterminate, the investigator should perform follow -up for 
the test result as per local procedures. Subjects tested positive for latent TB per work-
up may  be randomized to the trial if sufficient treatment has been initiated according 
to local routine clinical practice. Subjects positive for active TB per work -up are not 
eligible for the study . Subjects negative for TB per work -up (no signs of latent or 
active TB) may  be randomized to the trial if the work -up was conducted [ADDRESS_37365] result and a TB work- up (i.e., no second TB test 
will be performed), the TB test to assess eligibility  must have been done via the central 
laboratory  for the study  within the Screening Epoch (within 4 weeks prior to randomization) 
and TB work -up will only be considered if it was completed within [ADDRESS_37366] four weeks before randomization. Subjects positive for active TB per work -up are not 
eligible for the study . Subjects negative for TB per work -up (no signs of latent or active TB) 
may be randomized to the trial.

[COMPANY_001] Confidential Page 55
Amended Protocol Version 02 (Clean ) Protocol No. CAIN457M2301
Figure 8-[ADDRESS_37367] will not be eligible for randomization if "active tuberculosis is present" or if "latent 
tuberculosis is present and is untreated as per local guidelines". * If the first QuantiFERON®TB-Gold 
In-Tube assay (QFT) is indeterminate, the investigator may  choose to perform a second QFT or refer 
the subject for tuberculosis workup per local guidelines. ** If the result of QFT is "positive" or the 
results of 2 sequential QFTs are "indeterminate", the subject must be referred to have a tuberculosis 
workup per local guidelines (if no workup within 12 weeks prior to randomization is available). 

[COMPANY_001] Confidential Page 56
Amended Protocol Version 02 (Clean ) Protocol No. CAIN457M2301
8.[ADDRESS_37368] should be performed by  [CONTACT_37260].
In the event of a pandemic/epi[INVESTIGATOR_37202]-sitestudy 
visits, selected efficacy  assessments (excluding lesion count) can alternatively  be done via 
phone calls, virtual contacts or visits ofsite staff to the subject´s home, depending on local 
regulations and capabilities.
Efficacy  assessments based on Patient R eported Outcomes (PROs) might alternativel y be done 
remotely  fromthesubject´s home (e.g. online or by [CONTACT_37261]), depending on local 
regulations and technical capabilit ies.
8.3.1 Hidradenitis Suppurativa Clinical Response (HiSCR)
The HiSCR (Kimball et al 2014 ) is defined by [CONTACT_37262]: abscesses 
(fluctuant, with or without drainage, tender or painful), inflammator y nodules (tender, 
erythematous, pyogenic granuloma lesion), and draining fistulae (sinus tracts, with 
communications to skin surface, draining purulent fluid). The definition of responders to 
treatment (HiSCR achievers) is:
at least a 50% reduction in abs cesses and inflammatory  nodules (ANs),
no increase in the number of abscesses, and
no increase in the number of draining fistulas from baseline.
The HiSCR will be derived from the individual lesion counts of abscesses, nodules and fistulae 
at scheduled visits as indicated in the assessments schedule and as such will not be recorded in 
the eCRF.
Individual lesion count
The HS affected areas, e.g. right and left axillary (armpit), right and left gluteal ("buttock"), 
right and left inguinal -femoral (groin), perineal, pubic, sternal, right and left sub-mammary 
(breast) and others will be assessed by [CONTACT_37263], inflammatory  nodules, 
draining fistulas, total fistulas, and other lesions.
Whenever possible, the same ph ysician should perform the lesion count throughout the study .
Inflammatory  lesions, including abscesses, nodules, draining fistulae, total fistulae and other 
lesions will be counted by [CONTACT_37264].
Individual lesion counts will be performed for all lesions as outlined in the Table 8-1. The lesion 
count will include any existing and newl y observed lesions and will be recorded in the eCRF. 
The HS lesions are defined as ( Lipsker et al 2016 ; Zouboulis et al 2017 ):
Inflammatory nodules (N) that are t ypi[INVESTIGATOR_37203], deep -seated, three -dimensional, round, 
tender, ery thematous, infiltrated and possibly  pyogenic granuloma lesions with a diameter 
of >10 mm
Abscesses (A) that are often inflammatory ,painful, tender but fluctuating mass with a 
diameter of >10 mm, surrounded b y an erythematous area; the middle of an abscess 
contains pus

[COMPANY_001] Confidential Page 57
Amended Protocol Version 02 (Clean ) Protocol No. CAIN457M2301
Draining fistulae (DF); sinus tracts, raised, tender but fluctuating longitudinal mass of 
variable length and depth, with communications to skin surface, draining purulent fluid
Fistulae (F): total fistulae defined as sinus tracts, raised, tender but fluctuating 
longitudinal mass of variable length and depth, with communications to skin surface, both 
draining and non- draining purulent fluid.
8.3.2 Patient's Global A ssessment of Skin Pain - NRS in the past 24 hours
The Patient's Global Assessment of Skin Pain -Numerical Rating Scale (NRS) in the past 24 
hours will be used to assess pain “at its worst” and the average skin pain due to HS in the last 
24 hours. The NRS is a segmented numeric version of the visual analog scale (VAS) in which 
a respondent selects a whole number (0–10 integers) that best reflects the intensity of their pain 
ranging from 0 (no skin pain) to 10 (skin pa in as bad as you can imagine). Skin Pain will be 
collected as specified in the assessment schedule. To assess this, the patient should concentrate 
on the pain that his/her skin lesions generate. The Patient's Global Assessment of Skin Pain -
NRS will be completed by [CONTACT_37265].
8.3.3 Modified Hidradenitis Suppurativa Score (mHSS)
The Hidradenitis Suppurativa Score (Sartorius score) has been developed specificall y for HS to 
reflect disease severity  and has since been used as a modified score, mHSS, in clinical trials 
(Sartorius et al 2009 ; Kimball et al 2012 ) with minor simplifications when compared to the 
original score. The same seven anatomical areas as the HS-PGA are used. The following is 
recorded b y the dermatologist:
the anatomical regions involved: axilla, groin, gluteal (left ⁄right) or other region, 3 points 
per region;
the numbers and scores of lesions ( inflammatory  nodule or abscess - 1 point, draining 
fistula - 6 points) for each region;
the longest distance between two relevant lesions ( inflammatory  nodule, abscess or 
draining fistula) ,or size of lesion if single ,in each region: < 5 cm, 1 point; 5 –10 cm, 3 
points; > 10 cm, 9 points; and
whether all lesio ns in each region are separated by [CONTACT_37266]: y es, 0; no (= Hurley  III), 9 
points.
Regional scores are added and summed up to the patient’s total score. The upper limit of the 
scale is open. Results will be recorded in the eCRF.
Table 8-3 Modified Hidradenitis Suppurativa Score (mHSS)
Area evaluated Number Multiplier
Anatomical region involved: axilla, 
groin, gluteal (for all left ⁄right 
location) or other regionNumber of regions involved x3 per each region
Number and severity of lesions
Inflammatory nodules and 
abscesses Number of inflammatory nodules 
and abscessesx1 per each inflammatory nodul e 
or abscess
Draining fistula s Number of draining fistula s x6 per each fistula

[COMPANY_001] Confidential Page 58
Amended Protocol Version 02 (Clean ) Protocol No. CAIN457M2301
Area evaluated Number Multiplier
The longest distance between 2 
relevant lesions or size of lesion (if 
single in each region).Number of areas with the longest 
distance between 2 relevant 
lesions in each distance /size 
category<5 cm: x1 
5-10 cm: x3 > 10 cm: x9 
no active lesions: x0
Are all lesions clearly separated by 
[CONTACT_37266]?Number of areas in each category: 
with and without separation by 
[CONTACT_37267]: x0
No: x9
TOTAL SUM
8.3.4 HS-Physician’s Global A ssessment (HS -PGA )
The HS-PGA score is a static global severit y 6-point scale used and described by [CONTACT_37268] 
(Kimball et al 2012 ) (Table 8-4). It will be completed at scheduled visits as indicated in the 
Assessments schedule (Table 8-1). For a significant clinical response, at least a 2 point reduction 
is expected. The HS affected regions (e.g. right and left axillary , right and left gluteal (buttock), 
perianal, right and left inguinal- femoral (groin), others such as sub- mammary ) are assessed fo r 
abscesses, draining fistulas, inflammatory  nodules, and non-inflammatory  nodules and one 
global rating / score is assigned to each patient. The scores will be recorded in eCRF.
Table 8-4 Hidradenitis Suppurativa Physician's Global A ssessment Scale (HS -
PGA )
Score Rating Description
0 Clear 0 abscesses, 0 draining fistulas, 0 inflammatory nodules, and 0 non -inflammatory 
nodules
1 Minimal 0 abscesses, 0 draining fistulas, 0 inflammatory nodules, and presence of non -
inflammatory nodules
2 Mild 0 abscesses, 0 draining fistulas, and 1 -4 inflammatory nodules
or
1 abscess or draining fistula and 0 inflammatory nodules
3 Moderate 0 abscesses, 0 d raining fistulas, and ≥5 inflammatory nodules
or
1 abscess or draining fistula and ≥1 inflammatory nodules
or
2-5 abscesses or draining fistulas and <10 inflammatory nodules
4 Severe 2-5 abscesses or draining fistulas and ≥10 inflammatory nodules
5 Very severe >5 abscesses or draining fistulas
8.3.5 Dermatology  life quality  index (DLQI)
The Dermatology Life Quality Index (DLQI) is a 10 -item general dermatology disability index  
designed to assess health -related quality  of life (HRQoL) in adult subjects with skin diseases 
such as eczema, psoriasis, acne, and viral warts (Finlay andKhan 1994 ). The measure is self-
administered and includes domains of daily activities, leisure, personal relationships, symptoms 
and feelings, t reatment, and work/school. The measure is widely used: it has been tested across 
[ADDRESS_37369] week, 
and the instrument requires 1 to 2 minutes for completion. Each item has four response 
categories ranging from 0 (not at all) to 3 (very  much). “Not relevant” is also a valid response 
and is scored as 0. The DLQI total score is a sum of the 10 questions. Scores range from 0 to 

[COMPANY_001] Confidential Page 60
Amended Protocol Version 02 (Clean ) Protocol No. CAIN457M2301
Subject eDiary  training
At the initial study  visit (Screening Visit 1), subjects will complete the initial eDiary  training 
during which they  will learn to use the eDiary ’s protocol -specific and general features.
Subject and site training materials will be provided to the subject s and to the study  sites.
8.3.8 Patient Global Impression of severity (PGI -s)
Patient Global Impression of severit y (PGI -s) rates the severit y of the current HS on a scale 
ranging from "none" to "very severe". The PGI -s is self -administered and is to be complete d as 
per the assessment schedule on the electronic tablet at the investigational site. The PGI-s is 
based on the validated Clinical Global I mpression of severit y scale.
8.3.9 Patient Global Impression of Change (PGI- c)
The Patient Global Impression of change (PGI-c) is a patient -reported instrument that measures 
change in overall status on a scale ranging from one ("very  much improved") to seven ("very 
much worse"). PGI-c rates the current HS symptoms as compared to the start of the study  at 
visits indicated in the assessment schedule. The PGI-c is self-administered and is to be 
completed as per the assessment schedule on the electronic tablet at the investigational site. The 
PGI-c is based on the validated Clinical Global I mpression of change scale.
8.3.10 Work Producti vity and A ctivity Impairment Questionnaire: Specific 
Health Problem (WPA I-SHP)
The WPAI -SHP consists of six questions regarding current employ ment status, hours missed 
from routine work due to a disease/other reasons, the number of hours actually worked, a nd the 
degree to which HS affected productivit y/regular activities over the past seven days. WPAI 
outcomes are expressed as impairment percentages, with higher numbers indicating greater 
impairment and less productivity , i.e. worse outcomes.
8.3.11 Patient's lesi on count
This is a self-reported patient's assessed count of existing and new lesions in the HS affected 
areas. The Patient's lesion count will be implemented on the eDiary  and will be assessed on a 
weekl y basis.
8.3.[ADDRESS_37370] important domains in HS as proposed by 
[CONTACT_37226]  (Thorlacius et al 2018 ). The primary  endpoint used in this study , 
HiSCR, was developed and validated as part of the development program of adalimumab in HS. 
The HiSCR is considered to be adequately described and validated for its intended purpose as 
the primary  end-point in pi[INVESTIGATOR_36491] ( Humira (adalimumab) EPAR ).
The secondary  endpoint definition of flare is based on physician lesion counts and has been 
previously  used in clinical trials in HS. The secondar y endpoint of efficac y assessment used for 
evaluation of pain relief (NRS) is standard recommended primary  outcome measures for pain 
clinical trials, also supported by [CONTACT_7214] (FDA) and European Medicines 

[COMPANY_001] Confidential Page 61
Amended Protocol Version 02 (Clean ) Protocol No. CAIN457M2301
Agency  (EMA) guidelines. As chronic pain interferes with daily  activities and quality  of life, 
additional patient reported outcome measures (PROs ) of physical functioning and health- related 
quality  of life (HRQoL) tools are recommended for assessing the patient’s perception of the 
impact of disease and treatment on daily  life, physical, psychological and social functioning, 
and well -being. Therefor e, DLQI, EQ -5D, PGI -s, PGI -c and WPAI  are included as exploratory 
endpoints. These PROs are not disease specific, but applied conventionally  in other chronic 
diseases. The HS-specific exploratory  endpoints of HS-PGA and mHSS have been used in 
previous HS t rials.
8.4 Safet y
All blood draws and safety assessments should be done prior to study treatment administration. 
Appropriate safety  assessments (e.g., evaluation of AEs and SAEs including injection site 
reactions) should be repeated after the dose is administered.
In case of a global health event (e.g. pandemic, epi[INVESTIGATOR_901]) thatlimits or prevents on-site study 
visits, regular phone contacts or virtual calls, depending on feasibility  and technical 
requirements, will occur (approximately  every 4weeks, prior to home administration, or more 
frequentl y if needed) for safet y monitoring and discussion of thesubject´s health status until 
the subject can again visit the site. Events qualify ing for being reported in the case report form 
(e.g. AE, infection) shou ld be entered as appropriate.
If subjects cannot visit the site tohave blood/urine samples drawn for central lab 
analysis,investigator may consider performing the safety  lab tests locally, e.g. by [CONTACT_4677]´s general practitioner, in case it is needed to check safet y parameters.
If female subjects of child bearing potential cannot visit the siteto have urine pregnancy  tests 
done, urine pregnancy  test kitsmay be shipped or provided directl yto the subject (e.g. together 
with the study  drug). After appropriate instruction, subjects should perform the urine pregnancy 
test at home and report the result to the site. It is important thatsubjects do the pregnancy 
testfirstand only if the test result is negative proceed with the administration of thestudy 
drug. A communication process should be established with the subject so that the site is 
informed of the pregnancy  test results.
Alternativel y, depending on local regulations and capabilities, study  sitestaff may visit the 
subject at home todraw blood/ urine samples if needed .Sites should inform the Sponsor of 
proposed changes to sample management/ collection.
8.4.1 Physical examination
A physical examination, including general appearance, skin, neck, eyes, ears, nose, throat, lungs, 
heart, abdomen, back, lymph nodes, extremities, vascular and neurological systems will be 
performed as indicated in Table 8-1.
If necessary , based on medical history and/or s ymptoms, additional exams will be performed at 
the discretion of the investig ator.
Whenever possible, assessments for an individual subject should be performed by [CONTACT_37269] y site staff throughout the study.

[COMPANY_001] Confidential Page 62
Amended Protocol Version 02 (Clean ) Protocol No. CAIN457M2301
Information for all phy sical examinations must be included in the source documentation at the 
study  site. Significant findings that are present prior to the start of study treatment must be 
included in the Medical History  eCRF. Significant findings made after signing informed 
consent which meet the definition of an Adverse Event must be recorded on the Adverse E vent 
eCRF.
8.4.2 Vital signs
Vital signs (including blood pressure and pulse measurements) will be assessed at every 
scheduled visit as indicated in Table [ADDRESS_37371] has been sitting for five minutes, with back supported and both feet placed on 
the floor, heart rate, systolic and diastolic blood pressure will be measured twice
(measurements separated by 1 to 2 minut es) using a validated device, with an appropriatel y 
sized cuff. In case the cuff sizes available are not large enough for the subject’s arm 
circumference, a sphy gmomanometer with an appropriatel y sized cuff may be used. 
Measurements will be recorded in the source documentation and the average of the two 
measurements will be entered on the Vital Signs eCRF.
No specific action is pre-defined within this protocol to respond to specific abnormal vital signs, 
as it will be decided by  [CONTACT_37270] y abnormal values, taking into account the overall status of the subject.
8.4.3 Height and weight
Height and body weight will be measured as indicated in Table 8-1.
Height in centimeters (cm) and body  weight (to the nearest 0.1 kilogram (kg)) will be measured 
in indoor clothing, but without shoes. If possible, body  weight assessments should be performed 
by [CONTACT_37271] . The body 
weight recorded at the Randomization visit will be used to 
stratify  the subject population for 
randomization.
8.4.[ADDRESS_37372].

[COMPANY_001] Confidential Page 63
Amended Protocol Version 02 (Clean ) Protocol No. CAIN457M2301
[IP_ADDRESS] Hematology
Hemoglobin, hematocrit, red blood cell count, white blood cell count with differential 
(neutrophils including bands, lymphocy tes, monocy tes, eosinophils, basophils) and platelet 
count will be measured at all scheduled study  visits as specified in Table 8 -1.
[IP_ADDRESS].1 Erythrocyte sedimentation rate (ESR)
The ESR test will be performed locall y by [CONTACT_37272] . A laboratory  manual will be provided with detailed 
information on sample collection and handling. In order to preserve the blind, results of ESR 
will not be communicated to the other study  site staff, including the investigator, or to [COMPANY_001] 
during the stud y.
[IP_ADDRESS] Clinical chemistry
Serum chemistry  will include urea, creatinine, HbA1c, total bilirubin, AST (SGOT), ALT 
(SGPT), GGT , alkaline phosphatase, sodium, potassium, bicarbonate, calcium, phosphorous, 
total protein, albumin, lipase, amy lase, and uric acid. Serum chemistry  will be measured at all 
scheduled stud y visits as specified in Table 8 -1.
[IP_ADDRESS].1 Lipid panel
A lipid profile including High Density  Lipoprotein (HDL), Low Density  Lipoprotein (LDL), 
total cholesterol and triglycerides will be measured from a fasting blood sample as indicated in 
Table 8-1.
[IP_ADDRESS].2 High sensitivity C -reactive protein
High sensitivity  C-reactive protein (hsCRP) will be assessed centrall y as part of the clinical 
chemistry  panel as indicated in Table 8 -1. In order to preserve the blind, results of hsCRP will 
not be communicated to the study  site staff, including the investigator, or to [COMPANY_001] during the 
study .
[IP_ADDRESS] Local urinaly sis
Dipsticks will be provided by [CONTACT_37273]. Standard dipstick measurements for specific gra vity, protein, glucose, pH, blood, 
urine blood dipstick (non-hemoly zed), urine blood dipstick (hemoly zed), bilirubin, ketones and 
WBC will be done at scheduled visits as indicated in Table 8-1. If the standard dipstick result 
is positive, microscopy  assessments will be performed and recorded in the source data.
[IP_ADDRESS] Immunogenicity
Blood samples for immunogenicity  (IG, anti -secukinumab antibodies) will be taken pre-dose at 
the scheduled time points as indicated in Table 8-1. All blood samples (approximately  2 m L 
each) will be taken b y direct venipuncture.
The blood sample will be allowed to clot at room temperature prior to harvesting of the serum. 
The serum will be obtained by [CONTACT_7891], split into 2 aliquots and then stored at 
approximately  -70˚C to -20˚C prior to shipment on dry  ice to the central laboratory .

[COMPANY_001] Confidential Page 64
Amended Protocol Version 02 (Clean ) Protocol No. CAIN457M2301
For a detailed description of the blood sampling schema, including time points, refer to the 
Blood Log in Section16.2, Table 16-1.
A laboratory  manual will be provided by [CONTACT_37274], sample handling and shipment.
The actual sample collection date and exact time of collection will be entered on the eCRF 
capturing blood collection for IG. Sampling problems will be noted in the ‘Reason sample not 
taken’ section of the eCRF. In case unscheduled IG samples are taken, there should alway s be 
matching PK samples taken as well.
Immunog enicity  analytical method
An electrochemiluminescence -based method will be used for the detection of potential anti-
secukinumab antibody formation. A detailed description of the method to assess 
immunogenicit y will be described in the bioanal ytical raw data and in the respective 
Bioanal ytical Data Report (BDR).
8.4.[ADDRESS_37373] pregnancy  testing. 
Pregnancy  tests will be performed in all women of childbearing potential (see Section 5.2 for 
definition of childbearing potential), as indicated in Table 8-1.
Any woman with a confirmed positive pregnancy  test during screening is not eligible for 
randomization. A positive local urine pregnancy  test during the treatment periods of the study 
requires immediate interruption of study  treatment until a serum β -subunit of human chorionic 
gonadotropin (β-hCG) test is performed and found to be negative. If the serum β-hCG test is 
positive, the subject must be discontinued from the study  treatment.
Assessments of fertility
Medical documentation of oophorectom y, hysterectomy , or bilateral tubal ligation must be 
retained as source documents. Subsequent hormone level assessment to confirm the woman is 
not of childbearing potential must also be available as source documentation in the following 
cases:
1.surgical bilateral oophorectomy  without a hy sterectomy
2. reported 12 months of natural (spontaneous) amenorrhea with an appropriate clinical 
profile.
In the absence of the above medical documentation, FSH testing is required of any female 
subject, regardless of reported reproductive/menopausal status at screening/baseline.
8.4.[ADDRESS_37374] measures for a biologic 
immunomodulating agent in HS.

[COMPANY_001] Confidential Page 65
Amended Protocol Version 02 (Clean ) Protocol No. CAIN457M2301
8.5 Additional assessments
8.5.1 Clinical Outcome A ssessments (COA s)
The impact of HS on various aspects of subject’s health- related quality of life (HRQoL) will be 
assessed b y the following and are described in Section 8.3 :
Patient Global Assessment of Skin Pain (NRS)
Dermatology  Life Quality  Index (DLQI)
EuroQoL 9 Dimension Health Questionnaire -Health Status Questionnaire (EQ -5D-3 L)
Patient Global I mpression of severit y (PGI -s)
Patient Global I mpression of change (PGI -c)
Work Productivity  Activity  Impairment (WPAI )
HS Sy mptom Diary
All these questionnaires (except for questionnaires completed by [CONTACT_37275]'s Global Assessment of Pain NRS and HS Symptom Diary ) should be 
completed by [CONTACT_37276]. Responses to HRQoLs will be collected as per the eCOA manual on eDiary  or site pad.
All questionnaires will be completed in the language the respondent is most familiar with, at 
the scheduled visit before the subject sees the investigator for clinical assessments. The subject 
should be given sufficient space and time to complete the questionnaires. Before the investigator 
begins the clinical assessments, the study  coordinator should check the questionnaires for 
completeness and encourage the subject to complete an y missing responses.
After the investigator completes the clinical efficacy assessments (e.g. lesion count), the 
investigator will review and the examine questionnaires completed b y the subject for responses 
that may indicate potential AEs or SAEs. The investigator should review not only  the responses 
to the questions in the questionnaires but also for any unsolicited comments written by [CONTACT_1560]. If AEs or SAEs are confirmed then the investigator must record the events as per 
instructions given in Section 10of the protocol. The investigator/si te staff should not encourage 
the subject to change the responses reported in the completed questionnaires.
8.5.2 Pharmacokinetics
Details on sample collection, numbering, processing and shipment can be found in the 
Laboratory  Manual.
At all study  sites, blood samples will be collected pre-dose for PK analysis at the scheduled 
visits as indicated in Table 8-1.
For a detailed description of the blood sampling schema, including time points, refer to the 
Blood Collection L og in Table 16-1.
Blood samples (approximately  2 ml, not less than 1.5 ml) will be collected into Serum Separator 
Tubes (SST). All blood samples will be taken by  [CONTACT_37277]. The blood sample will be 
allowed to clot over a minimum of 30 minutes at room temperature prior to harvesting of the 
serum. The serum will be obtained by  [CONTACT_37278]. 2500 Revolutions Per Minutes 
(RPM) for 10 minutes. Thereafter, the serum samples will be placed on ice, split into 2 aliquots 

[COMPANY_001] Confidential Page 66
Amended Protocol Version 02 (Clean ) Protocol No. CAIN457M2301
(labelled plain barrier polypropylene tubes) and then stored (within 30 minutes of serum 
collection by [CONTACT_7891]) at -70˚C to -20˚C. The shipment to the central laboratory  should 
be made on dry ice. The shipment instructions will be provided by [CONTACT_2237] . If 
possible, each aliqu ot of a sample should be sent separately to the central laborator y. The back -
up samples should remain at the central laboratory  whereas the second batch (the second pair) 
is delivered to an anal ytical laboratory . Back -up samples at the Central Laboratory w ill only be 
disposed after approval by [CONTACT_37279] (t ypi[INVESTIGATOR_37204] 12 months after the 
clinical study  report (CSR) is published).
The actual sample collection date and exact time of collection should be entered in the Blood 
Collection for PK eCRF or in the Unscheduled Blood Collection for PK eCRF, as appropriate. 
Sampling problems should be noted in the ‘Reason sample not taken’ section of the eCRF.
PK sample handling, labeling and shipment instructions
A laboratory manual will be provi ded by [CONTACT_37280], handling and shipment.
Tubes and labels will be provided by [CONTACT_37281]/sample type and sample 
number pre -printed on the label.
Further details on labeli ng of the pharmacokinetics samples can be found in Table 16-1.
PK sample stability
Secukinumab is stable in serum samples for 4 months at -20°C or at -80°C. Long-term data 
confirmed a stabilit y of 39 months at -65°C to - 90°C.
PK analytical methods
An ELISA method will be used for the bioanalytical analysis of secukinumab in serum, with an 
anticipated lower limit of quantification (LLOQ) of 80 ng/ml. The detailed method description 
to assess secukinumab concentration will be described in the Bioanal ytical Data Report (BDR).
8.5.3 Biomarkers
[IP_ADDRESS] Additional biomarker assessments
[IP_ADDRESS].1 Exploratory serum biomarkers
Serum samples will be collected for exploratory  biomarkers.
Apart from hsCRP, as a general indicator of inflammation, no biomarkers are available which 
are validated and accepted to assess disease stage, severit y, efficacy of treatments or 
stratification of HS patients for targeted treatments. Therefore, serum samples will be collected 
for exploratory  biomarker assessments.

[COMPANY_001] Confidential Page 68
Amended Protocol Version 02 (Clean ) Protocol No. CAIN457M2301
With the advances in technology over time, the mos t appropriate technology will be used at the 
time the exploratory  DNA research is performed. This may include the study  of the entire 
genome (whole genome sequencing).
Laboratory  Manual will contain detailed information on sample collection, handling, and 
shipment.
8.5.4 Other A ssessments
[IP_ADDRESS] Trial feedback questionnaire
This trial will include an option for subjects to complete an anon ymized questionnaire, referred 
to as a ‘Trial Feedback Questionnaire’. This questionnaire will give subjects an opportunity  to 
provi de feedback on their clinical trial experience. Individual subject level responses will not 
be reviewed by [CONTACT_431]. Responses will be used by [CONTACT_456] ([COMPANY_001]) to understand 
where improvements can be made in the clinical trial process. This questionnaire does not 
collect data about the subject's disease, symptoms, treatment effect or adverse events, and 
therefore is not considered trial data. Should any spontaneous information be collected about 
AEs, this will be transferred to the safety  databas e.
[IP_ADDRESS] Health Care Resource Utilization
Studies conducted in Canada and the [LOCATION_002] have indicated the high economic impact of 
the disease both on a direct level (due to hospi[INVESTIGATOR_37205]) and 
on an indirect level (occupational disability ). All-cause and HS-related outpatient visits, 
inpatient stays and emergency  visits not planned per protocol will be collected to explore 
possible decreases in utilization of these resources. Health Care Resource Utilization will be
entered on eCRF.
[ADDRESS_37375] if, he/she believes that 
continuation would negative ly impact the subject's well -being.
Study  treatment must be discontinued under the following circumstances:
Subject's wish
Withdrawal of consent
Pregnancy
Ongoing use of prohibited treatment as per the prohibited treatment Section 6.2.2
Any situation in which study  participation might result in a safet y risk to the subject

[COMPANY_001] Confidential Page 69
Amended Protocol Version 02 (Clean ) Protocol No. CAIN457M2301
Following emergency  unblinding
Emergence of the following adverse events: an y adverse events that in the judgment of the 
investigator/qualified site staff , taking into account the subject’s overall status, prevent the 
subject from continuing study treatment (for example, sepsis)
Any laboratory  abnormalities that in the judgment of the investigator/qualified site staff, 
taking into consideration the subject’ s overall status, prevents the subject from continuing 
study  treatment
If discontinuation of study  treatment occurs, the investigator should make a reasonable effort 
to understand the primary reason for the subject’s premature discontinuation of study trea tment 
and record this information in the eCRF.
Subjects who discontinue study  treatment should NOT be considered withdrawn from the study 
UNLESS they withdraw their consent (see Withdrawal of Informed Consent, Section 9.1.2 ). 
Where possible, they should continue attending site visits for the assessments indicated in 
the assessment schedule (including efficacy assessments). If the subject does not wish to attend 
any further visits, the subject should return to the site after discontinuation of study  drug, for an 
End of Treatment (EOT) visit and Follow -up visit (F8). Assessments detailed in the EOT and 
Follow -up visit (F8) in Table 8-[ADDRESS_37376] 
fails to return for these assessments for unknown reasons, every  effort (e.g. telephone, e-mail, 
letter) should be made to contact [CONTACT_423]/pre -designated contact [CONTACT_37282] -
up section (Section 9.1.3 ). This contact [CONTACT_37283] y be done according to the 
study  visit schedule.
If the subject cannot or is unwilling to attend any  visit(s), the site staff should maintain regular 
telephone contact [CONTACT_1155], or with a person pre-designated by [CONTACT_24362]. This 
telephone contact [CONTACT_6636].
The investigator must also contact [CONTACT_37284]’s discontinuation from study  
treatment.
If discontinuation occurs because treatment code has been broken, please refer to Emergenc y 
breaking of treatment code section.
9.1.[ADDRESS_37377]:
Does not want to participate in the study  anymore
and
Does not want an y further visits or assessments
and
Does not want an y further study related contacts
and
Does not allow anal ysis of already  obtained biologic material

[COMPANY_001] Confidential Page 70
Amended Protocol Version 02 (Clean ) Protocol No. CAIN457M2301
In this situation, the investigator should make a reasonable effort (e.g. telephone, e -mail, letter) 
to understand the primary reason for the subject’s decision to withdraw his/her consent and 
record this information.
Study  treatment must be discontinued and no further assessments conducted , and the data that 
would have been collected at subsequent visits will be considered missing.
Further attempts to contact [CONTACT_5366] -up.
All efforts should be made to complete the assessments prior to study  withdrawal. A final 
evaluation at the time of the subject’s study  withdrawal should be made as detailed in the 
assessment table.
[COMPANY_001] will continue to retain and use all research results (data) that have alread y been 
collected f or the study  evaluation.
9.1.[ADDRESS_37378] show "due diligence" by 
[CONTACT_37285], e.g. dates of telephone 
calls, registered letters, etc. A subject should not be considered as lost to follow -up until due 
diligence has been completed or until the end of the study .
9.1.4 Early  study termination by  [CONTACT_37286]. This may  include reasons 
related to the benefit/ risk assessment of participating in the study , practical reasons (including 
slow enrollment), or for regulatory  or medical reasons. In taking the decision to terminate, 
[COMPANY_001] will alway s consider the subject welfare and safet y. Should early  termination be 
necessary , subjects must be seen as soon as possible (and be provided instructions on when the 
subject should stop self-adminis tration of study  drug and come for a final visit) and treated as 
a prematurely  withdrawn subject. The investigator may be informed of additional procedures 
to be followed in order to ensure that adequate consideration is given to the protection of the 
subject’s interests. The investigator or sponsor depending on the local regulation will be 
responsible for informing Institutional Review Board/I ndependent Ethics Committee (IRB/IEC) 
of the early  termination of the trial.
9.[ADDRESS_37379] completed the study  when she/he has completed the last 
visit planned in the protocol (visit at Week 52 or visit at Week 60 (F8)). The Study Completion 
visit for individua l patient will be defined as:

[COMPANY_001] Confidential Page 71
Amended Protocol Version 02 (Clean ) Protocol No. CAIN457M2301
Week 60 (F8) visit for subjects who prematurely discontinue study  treatment in Treatment 
Periods 1 or 2 for an y reason, or subjects who complete treatment period but do not enroll 
in the planned extension study
Week 52 visit f or subjects continuing in the planned extension study
At the end of the stud y, patients who completed the core stud y treatment period are expected to 
benefit from study  treatment based on the investigator's clinical judgement, and wish to 
participate will be eligible to continue into a planned extension study . The extension study  is 
intended to collect further safet y and efficacy data on secukinumab, provide continuous access 
to treatment for patients and evaluate the sustainability  of the treatment effect after study  drug 
discontinuation (in the randomized withdrawal part of this study ).
The investigator must provide follow -up medical care for all subjects who are pre-maturel y 
withdrawn from the study  or do not continue in the extension study , or must refer them for 
appropriate ongoing care. This care may include use of long term antibiotics, surgical 
intervention and/or use of biologics.
10 Safety  monitoring and reporting
10.1 Definition of adverse events and reporting requirements
10.1.1 Adverse events
An adverse event (AE) is any untoward medical occurrence (e.g., any unfavorable and 
unintended sign [including abnormal laboratory  findings], sy mptom or disease) in a subject or 
clinical investigation subject after providing written informed consent for participation in the 
study . Therefore, an AE may  or may  not be temporally  or causall y associated with the use of a 
medicinal (investigational) product.
In addition, all reports of intentional misuse and abuse of the product are also considered an 
adverse event irrespective if a clinical event has occurred.
The investigator has the responsibility  for managing the safet y of individual subject and 
identify ing adverse events.
[COMPANY_001] qualified medical personnel will be readily  available to advise on trial related medical 
questi ons or problems.
The occurrence of adverse events must be sought by [CONTACT_105] -directive questioning of the subject at 
each visit during the study. Adverse events also may be detected when they are volunteered b y 
the subject during or between visits or through phys ical examination findings, laboratory  test 
findings, or other assessments.
Adverse events must be recorded in the Adverse Events eCRF under the signs, symptoms or 
diagnosis associated with them, accompanied by  [CONTACT_6644] (as far as possibl e) 
(if the event is serious refer to Section 10.1.2 ):
1.The severit y grade.
mild: usually  transient in nature and generally  not interfering with normal activities
moderate: sufficiently discomforting to interfere with normal activities

[COMPANY_001] Confidential Page 72
Amended Protocol Version 02 (Clean ) Protocol No. CAIN457M2301
severe: prevents normal activities .
2. Its relationship to the study  treatment (suspected: Yes/No). If the event is due to lack of 
efficacy  or progression of underl ying illness (i.e. progression of the study  indication), the 
assessment of causality  will usually  be ‘Not suspected’. The rationale for this guidance is 
that the sy mptoms of a lack of efficacy  or progression of underl ying illness are not caused 
by [CONTACT_6645], they  happen in spi[INVESTIGATOR_6532]/or both lack of effi cacy and 
progression of underly ing disease can only  be evaluated meaningfull y by [CONTACT_37287], not on a single subject.
3. Its duration (start and end dates) or if the event is ongoing, an outcome of not 
recovered/not resolved must be reported.
4. W hether it constitutes a serious adverse event (SAE -see Section 10.1.2 for definition of 
SAE) and which seriousness criteria have been met.
5. A ction taken regarding with study  treatment.
All adverse events must be treated appropriately . Treatment may include one or more of the 
following:
dose not changed
dose reduced/increased
drug interrupted/withdrawn
6. C oncomitant medication or non -drug therap y given
7. Its outcome
not recovered/not resolved
recovered/resolved
recovered/resolved with sequelae
fatal
unknown
Conditions that were alread y present at the time of informed consent should be recorded in 
medical history  of the subject.
Adverse events (including lab abnormalities that constitute AEs) should be described using a 
diagnosis wh enever possible, rather than individual underly ing signs and s ymptoms.
Adverse event monitoring should be continued for at least [ADDRESS_37380] be followed until its resolutio n or until it is judged to 
be permanent (e.g. Continuing at the end of the study ), and assessment must be made at each 
visit (or more frequently, if necessary) of an y changes in severity, the suspected relationship to 
the study  drug, the interventions requ ired to treat it, and the outcome.
Information about adverse drug reactions for the investigational drug can be found in the 
Investigator's Brochure (IB).
Abnormal laboratory  values or test results constitute adverse events only if they fulfill at least 
one of the following criteria:
they induce clinical signs or sy mptoms

[COMPANY_001] Confidential Page 73
Amended Protocol Version 02 (Clean ) Protocol No. CAIN457M2301
they are considered clinically  significant
they require therapy
Clinically  significant abnormal laboratory  values or test results must be identified through a 
review of values outside of normal ranges/clinically  notable ranges, significant changes from 
baseline or the previous visit, or values which are considered to be non -typi[INVESTIGATOR_37206]. Alert ranges for laboratory and other test abnormalities are included in 
Section 16.1 .
10.1.2 Serious adverse events
An SAE is defined as any adverse event [appearance of (or worsening of any pre-existing)], 
undesirable sign(s), symptom(s) or medical conditions(s) which meets any one of the followin g 
criteria:
fatal
life-threatening
Life-threatening in the context of a SAE refers to a reaction in which the subject was at risk of 
death at the time of the reaction; it does not refer to a reaction that hypothetically  might have 
caused death if it were m ore severe (please refer to the I CH-E2D Guidelines).
results in persistent or significant disability /incapacity
constitutes a congenital anomaly /birth defect
requires inpatient hospi[INVESTIGATOR_1081], unless 
hospi[INVESTIGATOR_062]: 
routine treatment or monitoring of the studied indication, not associated with any  
deterioration in condition 
elective or pre -planned treatment for a pre-existing condition that is unrelated to the 
indication under study  and has not worsened since signing the informed consent
social reasons and respi[INVESTIGATOR_37207]’s 
general condition
treatment on an emergency  outpatient basis for an event not fulfilling any  of the 
definitions of a SAE given above and not resulting in hospi[INVESTIGATOR_063]
is medically  significant, e.g. defined as an event that jeopardizes the subject or may  
require medical or surgi cal intervention to prevent one of the outcomes listed above
Medical and scientific judgment should be exercised in deciding whether other situations should 
be considered serious reactions, such as important medical events that might not be immediately 
life threatening or result in death or hospi[INVESTIGATOR_37208]. Such events should be 
considered as “medicall y significant”. Examples of such events are intensive treatment in an 
emergency  room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do 
not result in hospi[INVESTIGATOR_37209] (please refer to the ICH-
E2D Guidelines) .
Allmalignant neoplasms will be assessed as serious under “medically  significant” if other 
seriousness criteria are not met .

[COMPANY_001] Confidential Page 74
Amended Protocol Version 02 (Clean ) Protocol No. CAIN457M2301
Any suspected transmission via a medicinal product of an infectious agent is also considered a 
serious adverse reaction.
All reports of intentional misuse and abuse of the product are also considered serious adverse 
event irrespective if a clinical event has occurred.
10.1.[ADDRESS_37381] be reported to [COMPANY_001] safet y within 24 hours of learning of its occurrence. 
Detailed instructions regarding the submission process and requirements are to be found in the 
investigator folde r provided to each site.
1. Screen Failures (e.g. A subject who is screened but is not treated or randomized): SAEs 
occurring after the subject has provided informed consent until the time the subject is 
deemed a Screen Failure must be reported to [COMPANY_001].
2. Randomized OR Treated Subjects: SAEs collected between time subject signs ICF until 
[ADDRESS_37382] be reported separatel y as a new event.
If the SAE is not previously documented in the Investigator’s Brochure or Package Insert (new 
occurrence) and is thought to be related to the study  treatment, a CMO & PS Department 
associate may urgentl y require further information from the investigator for health authorit y 
reporting. [COMPANY_001] may need to issue an Investigator Notification (IN) to inform all 
investigators involved in any study  with the same study  treatment that this SAE has been 
reported.
Suspected Unexpected Serious Adverse Reactions (S[LOCATION_003]Rs) will be collected and reported to 
the competent authorities and relevant ethics committees in accordance with EU Guidance 
2011/C 172/[ADDRESS_37383]’s last visit will be reported 
in the AE eCRF. SAEs bey ond that date will only  be recorded in the Safet y database.
10.1.[ADDRESS_37384] be reported to [COMPANY_001] within 24 hours of learning of its occurrence. 
The pregnancy  should be followed up to determine outcome, including spontaneous or 

[COMPANY_001] Confidential Page 75
Amended Protocol Version 02 (Clean ) Protocol No. CAIN457M2301
voluntary  termination, details of the birth, and the presence or absence of any birth defects, 
congenital abnormalities, or maternal and/or newborn complications.
Pregnancy  should be recorded and reported by [CONTACT_37288]  (CMO&PS). Pregnancy  follow -up should be recorded on the same 
form and should include an assessment of the possible relationship to the study treatment any 
pregnancy  outcome. Any SAE experienced during pregnancy  must be reported.
10.1.5 Reporting of study treatment errors including misuse/abuse
Medication errors are unintentional errors in the prescribing, dispensing, administration or 
monitoring of a medicine while under the control of a healthcare professional, subject or 
consumer (European Medicines Agency  definition).
Misuse refers to situations where the medicinal product is intentionally  and inappropriatel y used 
not in accordance with the prot ocol.
Abuse corresponds to the persistent or sporadic, intentional excessive use of a medicinal product, 
which is accompanied b y harmful ph ysical or ps ychological effects.
Study  treatment errors and uses outside of what is foreseen in the protocol will be collected in 
the DAR (dose administration record) eCRF irrespective of whether or not associated with an 
AE/SAE and reported to Safety  only if associated with an SAE. Misuse or abuse will be 
collected and reported in the safet y database irrespective of it being associated with an AE/SAE 
within 24 hours of I nvestigator’s awareness.
Table 10-1 Guidance for capturing the study  treatment errors including 
misuse/abuse
Treatment error ty peDocument in Dose Administration 
(DAR) eCRF (Yes/No)Document in AE 
eCRF Complete SAE form
Unintentional study 
treatment errorYes Only if associated 
with an AEOnly if associated with 
an SAE
Misuse/Abuse Yes Yes Yes, even if not 
associated with a SAE
For more information on AE and SAE definition and reporting requirements, please see the 
respective sections.
10.2 Additional Safety  Monitoring
Not applicable. 
10.2.1 Data Monitoring Committee
This study  will include a Data Monitoring Committee (DMC) that will function independently 
of all other individuals associated with the conduct of the clinical trial, including the site 
investigators participating in the stud y. The DMC will assess  
 the progress of a clinical trial, safet y data, and critical efficacy  variables, and it will 
recommend to the sponsor whether to continue, modify  or terminate a trial.

[COMPANY_001] Confidential Page 76
Amended Protocol Version 02 (Clean ) Protocol No. CAIN457M2301
Specific details regarding the composition, responsibilities, data monitoring and meeting 
frequency , and documentat ion of DMC reports, minutes, and recommendations will be 
described in a separate charter that is established between the sponsor and the DMC.
10.2.2 Steering Committee
A Steering Committee (SC) will be established comprising disease area experts, investigators 
participating in the trial, i.e. not being members of the DMC and [COMPANY_001] representatives from 
the CTT.
The SC will ensure transparent management of the study  according to the protocol by 
[CONTACT_37289]. The SC will review 
protocol amendments as appropriate. Together with the clinical trial team, the SC will also 
develop recommendations for publication of study  results. The details of the role of the steerin g 
committee will be defined in the Steering Committ ee Charter.
[ADDRESS_37385] that allows its accurate reporting, 
interpretation and verification.
Designated investigator staff will enter the data required by [CONTACT_37290] (eCRF). The eCRFs have been built using fully validated secure web-
enabled software that conforms to [ADDRESS_37386] been trained. Automatic validation programs 
check for data discrepancies in the eCRFs, allow modification and/or verification of the entered 
data b y the investigator staff.
The investigator/designee is responsible for assuring that the data (entere d into eCRF) is 
complete, accurate, and that entry  and updates are performed in a timely  manner. The 
Investigator must certify  that the data entered are complete and accurate
After final database lock, the investigator will receive copi[INVESTIGATOR_37210].
11.2 Database management and quality  control
[COMPANY_001] personnel (or designated contract research organization (CRO)) will review the data 
entered by [CONTACT_5375] . Electronic data queries stating 
the nature of the problem and requesting clarification will be created for discrepancies and 
missing values and sent to the investigational site via the EDC s ystem. Designated investigator 
site staff are required to respond promptly to q ueries and to make an y necessary  changes to the 
data.
Concomitant treatments and prior medications entered into the database will be coded using the 
World Health Organization (WHO )Drug Reference List, which employ s the Anatomical 
Therapeutic Chemical classification system. Medical history /current medical conditions and 

[COMPANY_001] Confidential Page 77
Amended Protocol Version 02 (Clean ) Protocol No. CAIN457M2301
adverse events will be coded using the Medical Dictionary  for Regulatory  Activities (MedDRA) 
terminology .
Laboratory  samples will be processed centrall y and the results will be sent electronicall y to 
[COMPANY_001] (or a designated CRO).
Subjects will fill in their PRO data in a site based tablet. The system will be supplied by a 
vendor, who will also manage the database. The database will be sent electronically  to [COMPANY_001] 
personnel (or designated CRO).
Randomization codes and data about all study  treatment (s) dispensed to the subject and all 
dosage changes will be tracked using an Interactive Response Technology (IRT). The system 
will be supplied by a  vendor, who will also manage the database. The data will be sent 
electronically  to [COMPANY_001]/ (or a designated CRO) at specific timelines.
Each occurrence of a code break via I RT will be reported to the clinical team a nd monitor. The 
code break functionality  will remain available until study  shut down or upon request of [COMPANY_001].
Once all the necessary  actions have been completed and the database has been declared to be 
complete and accurate, it will be locked and the t reatment codes will be unblinded and made 
available for data analysis.Any changes to the database after that time can only be made after 
written agreement b y [COMPANY_001] development management.
DNA  samples:
To maximize confidentiality , all samples and the in formation associated with the samples will 
be double -coded to prevent the exposure of the subject’s information and identity . This double -
coding process allows [COMPANY_001] to go back and destroy  the sample at the subject’s request. In 
addition, sample informa tion is stored in one secured database while genetic data is stored in 
an independent secured database.
The use of DNA to search for biomarkers of disease and drug action is explorator y. An y results 
from this DNA study  will not be placed in the subject’s m edical records.
11.3 Site monitoring
Before study  initiation, at a site initiation visit or at an investigator’s meeting, a [COMPANY_001] 
representative will review the protocol and data capture requirements (i.e. eCRFs) with the 
investigators and their staff. Durin g the study , [COMPANY_001] employ s several methods of ensurin g 
protocol and GCP compliance and the quality/integrit y of the sites’ data. The field monitor will 
visit the site to check the completeness of subject records, the accuracy  of data capture / data 
entry, the adherence to the protocol and to Good Clinical Practice, the progress of enrollment, 
and to ensure that study  treatment is being stored, dispensed, and accounted for according to 
specifications. Key study personnel must be available to assist the field monitor during these 
visits. Continuous remote monitoring of each site’s data may be performed by a centralized 
[COMPANY_001] CRA organization. Additionally , a central analy tics organization may  analyze data & 
identify  risks & trends for site operational pa rameters, and provide reports to [COMPANY_001] clinical 
teams to assist with trial oversight.
The investigator must maintain source documents for each subject in the study , consisting of 
case and visit notes (hospi[INVESTIGATOR_5320]) containing demog raphic and medical 

[COMPANY_001] Confidential Page 78
Amended Protocol Version 02 (Clean ) Protocol No. CAIN457M2301
information, laboratory data, electrocardiograms, and the results of any other tests or 
assessments. All information on eCRFs must be traceable to these source documents in the 
subject’s file. The investigator must also keep the original informed consent form signed by [CONTACT_1560] (a signed cop y is given to the subject).
The investigator must give the monitor access to all relevant source documents to confirm their 
consistency  with the data capture and/or data entry . [COMPANY_001] monitoring s tandards require full 
verification for the presence of informed consent, adherence to the inclusion/exclusion criteria, 
documentation of SAEs, and of data that will be used for all primary  variables. Additional 
checks of the consistency  of the source data with the eCRFs are performed according to the 
study -specific monitoring plan. No information in source documents about the identity  of the 
subjects will be disclosed.
In the event of a major health care disruption (e.g. pandemic, epi[INVESTIGATOR_901]), requiring social 
distancing or limited travel/attendance to site, remote site initiation and monitoring could be 
considered.
12 Data analy sis and statistical methods
Any data analy sis carried out independently  by [CONTACT_37291].
12.1 Analysis sets
The Randomized Analysis Set (RAS) consists of all randomized subjects. Subjects will be 
analyzed according to the treatment assigned to at randomization.
The Full Anal ysis Set (FAS) comprises all subjects to whom study treatment has been assigned. 
Subjects will be analy zed according to the treatment assigned to at randomization. Mis-
randomized subjects (mis-randomized in IRT) will be excluded from FAS. Mis-randomized 
subjects are defined as cases where IRT contacts were made by [CONTACT_37292] y or 
inappropriatel y prior to confirmation of the subject’s final randomization eligibility  and no 
study  medication was administered to the subject.
The Safet y Set includes all subjects who received at least one dose of study treatment. Subjects 
will be anal yzed according to the stud y treatment received, where treatment received is defined 
as the randomized/assigned treatment if the patient took at least one dose of that treatment or 
the first treatment received if the ra ndomized/assigned treatment was never received.
For all analysis in Treatment Period 1, the Placebo group to secukinumab [ADDRESS_37387] demographics and other baseline characteristics data will be based on 
Randomized Analy sis Set.

[COMPANY_001] Confidential Page 79
Amended Protocol Version 02 (Clean ) Protocol No. CAIN457M2301
Demographics and baseline characteristics
Summary  statistics will be presented for continuous demographic and baseli ne characteristic 
variables for each treatment group and for all subjects. The number and percentage of subjects 
in each category will be presented for categorical variables for each treatment group and for all 
subjects.
Medical history
Any condition entered as medical history  or current medical conditions at baseline will be coded 
using the MedDRA dictionary . Medical history  will be summarized by  [CONTACT_37293] .
12.[ADDRESS_37388] certain thresholds (e.g., an y exposure, 
≥1 week, ≥2 weeks, ≥3 weeks, ≥4 weeks, ≥8 weeks, etc.) will be display ed.
Prior and concomitant treatments
Prior and concomitant treatments will be summarized by  [CONTACT_37294] y Set.
Prior treatments are defined as treatments taken and stopped prior to first dose of study 
treatment. An y treatment given at least once between the day of first dose of randomized stud y 
treatment and the last day of study  visit will be a concomitant treatment, including those that 
were started pre -baseline and continued into the treatment period.
Treatments will be presented in alphabetical order, by [CONTACT_37295]. Tables will 
also show the overal l number and percentage of subjects receiving at least one treatment of a 
particular ATC code and at least one treatment in a particular anatomical main group.
In addition, medical procedures and significant non-drug therapi[INVESTIGATOR_37211].
12.4 Analysis of the primary  endpoint(s)
The primary  aim of the study  is to demonstrate the efficacy  of two secukinumab regimens 
compared to placebo with respect to HiSCR after 16 weeks of treatment. The detailed definition 
and the justification of the corresponding primary  Estimand, as well as the definition of the 
supplementary  Estimands will be provided in the Statistical Analy sis Plan.
12.4.1 Definition of primary  endpoint(s)
The primary  endpoint of the study  is HiSCR at Week 16, defined as at least a 50% decrease in 
Abscess and inflammatory  Nodule (AN) count compared to baseline with no increase in the 

[COMPANY_001] Confidential Page 80
Amended Protocol Version 02 (Clean ) Protocol No. CAIN457M2301
number of abscesses and/or in the number of draining fistulas from baseline to Week 16. The 
baseline is defined as the last assessment (including unschedul ed visits) obtained before/on 
theday ofthefirst administration of the study treatment, or on the randomization date 
ifthere has been no drug administration. The anal ysis of the primary endpoint will be based on 
the FAS .
12.4.2 Statistical model, hypothesis, a nd method of analy sis
The statistical h ypotheses for the primary  endpoint being tested is that there is no difference in 
the proportion of HiSCR at Week 16 in any of the secukinumab regimens versus placebo 
regimen.
Let pj denote the proportion of HiSCR at Week 16 for treatment regimens j, j = 0, 1, 2 where
0 corresponds to placebo regimen,
1 corresponds to secukinumab 300 mg q2w s.c.,
2 corresponds to secukinumab 300 mg q4w s.c.,
In statistical terms, Hj: pj= p0, HAj: pj≠ p0 for the jth secukinumab regimen, i.e.
H1: secukinumab [ADDRESS_37389] to HiSCR 
after 16 weeks of treatment.
H2: secukinumab [ADDRESS_37390] to HiSCR 
after 16 weeks of treatment.
The prima ry analysis method will be logistic regression with treatment group, geographical 
region, Hurley  stage, use of antibiotic, baseline body  weight and baseline AN counts as 
explanatory  variables. Odds ratios will be computed for comparisons of secukinumab dose 
regimens versus placebo utilizing the logistic regression model fitted. In case of response rates 
of 0% or of 100% in one of the treatment groups, Fisher’s exact test will be applied. Risk 
difference and confidence intervals for risk difference will be p rovided.
The detailed testing strategy  including the primary  endpoint analysis is provided in Section 12.[ADDRESS_37391] to HiSCR after 16 
weeks of treatment could be demonstrated if H1 and/or H2is/are rejected and the treatment 
effect is in favor of secukinumab.
12.4.3 Handling of missing values/censoring/discontinuations
Missing data for primar y and secondar y endpoints will be addressed using multiple imputation.
As these endpoints are binary  outcomes derived from underl ying continuous variables, the 
imputations will be performed on those continuous variables, from which the imputed binary 
outcomes will then be constructed. Subjects who discontinue from study  treatment early will 
be encouraged to stay in the study and are considered as retrieved dropout (RDO) subjects. The 
analysis will account for different post-randomization events for missing data handling as 
follows:
Permanent discontinuation of study treatment due to AE (Adverse Event), LoE (Lack of 
Efficacy): If retrieved dropout data are available, these will be used for analysis. If no data was 
retrieved after study treatment discontinuation, missing data will be multiply imputed based on 

[COMPANY_001] Confidential Page 81
Amended Protocol Version 02 (Clean ) Protocol No. CAIN457M2301
placebo arm data (Carpenter et al 2013 ). More details on the imputation model will be specified 
in the Statistical AnalysisPlanprior to unblinding.
Permanent discontinuation of study treatment due to other reasons than AE (Adverse 
Event), LoE (Lack of Efficacy): If efficacy  data collected after study  treatment discontinuation 
are available (retrieved dropout), then the retrieved drop -out data will be excluded and missing 
data after study  treatment discontinuation will be multiply  imputed using the MAR (missing at 
random) assumption. In case of a major health event (e.g. pandemic/epi[INVESTIGATOR_901]), the number of 
missing measurements may increase and the potential to recover information for the main 
endpoints from intermediate measurements that have been dropped from the visit schedule may 
decrease. This may  affect the power of tests and the precision of estimates for this study .
Furthermore, the Sponsor might consider additional anal yses to assess any potential impact of 
a major health event on our study  results. Detailed information, including missing data handling 
plan and additional anal ysis, will be specified in the Statistical Analysis Plan.
12.4.[ADDRESS_37392] screening visit (with weight 1/6) and the second screening visit (with weight 
2/6) and the randomization visit (with weight 3/6). This weighted average is being used during 
the study  to identify  the need for rescue medication and it is also used at Week 52 to identify 
responders being randomiz ed in the extension study.
Supportive analy ses
A supplementary  estimand, which is detailed inthe Statistical Analysis Plan,and following 
analyses will also be done to support primary  endpoints:
The number and percentage of subjects will be presented for proportions of subjects who 
achieved at least 50%, 75% and 100% reductions in the AN count relative to Baseline 
(AN50, AN75, AN100).
Summary  statistics will be presented for absolute and percent change from Baseline in AN 
count.
Summary  statistics will be presented for absolute and percent change from Baseline in 
number of abscesses.
Summary  statistics will be presented for absolute and percent change from Baseline in 
number of inflammatory  nodules.
Summary  statistics will be presented for absolute and perc ent change from Baseline in 
number of draining fistulas.

[COMPANY_001] Confidential Page 82
Amended Protocol Version 02 (Clean ) Protocol No. CAIN457M2301
12.5 Analysis of secondary  endpoints
12.5.1 Efficacy  and/or Pharmacody namic endpoint(s)
The secondary  endpoints of this study  are planned as follow:
Percentage change from baseline in AN count at Week 16.
Flare over 16 weeks: Patients who experience at least one flare over [ADDRESS_37393] a 25% increase in AN counts with a minimum increase of 2 AN 
relative to baseline.
Pain/NSR30 at Week 16: Patients achieving NRS30 at Week 16, among pat ients with 
baseline NRS ≥ 3. NRS30 is defined as at least 30% reduction and at least 2 unit reduction 
from baseline in Patient's Global Assessment of Skin Pain. NRS from baseline to Week 16 
is the weekl y average score calculated based on the 7 available da ily scores: Baseline 
(Week 0) will be average of NRS score from day  -7 to day  -1, week 1 will be average of 
score from day  1 to day  7, week 2 will be average of score from day  8 to day  14 and so 
on.For an y week with less than 4 diary  entries within the we ek, the weekly  average will 
be recorded as missing.
For the secondary  endpoint of percentage change in AN count from baseline to Week 16, an 
analysis of covariance (ANCOVA) model will be fitted to estimate the treatment differences 
between the two secukinumab regimens and placebo with treatment group, baseline AN count, 
Hurley  stage, use of antibiotic, geographical region andbaseline bod y weight as covariates.
The analysis method for both flare up to Week 16 and Pain/NRS30 at Week 16will be the 
logistic regression: with treatment group, Hurley  stage, geographical region, use of antibiotic, 
baseline bod y weight and baseline AN counts as explanatory  variables for flare endpoints; and 
with treatment group, Hurley  stage, region, use ofantibiotic, baseline body  weight and baseline 
NRS as explanatory  variables for pain endpoints. Odds ratios will be computed for comparisons 
of secukinumab dose regimens versus placebo utilizing the logistic regression model fitted. In 
case of response rat es of 0% or of 100% in one of the treatment groups, Fisher’s exact test will 
be applied. Risk difference and confidence intervals for risk difference will be provided.
Testing strategy
Two studies of identical design (CAIN457M2301 and CAIN457M2302) are planned, each with 
multiple endpoints. Primary  endpoint , secondary endpoints percentage change from baseline in 
AN count at Week 16andflare over 16 weeks will be tested in each of the two studies separatel y. 
Pain/NSR30 at Week 16 will be tested using the combined data from the two studies. In order 
to control for the type-I error rate (“false positive rate”) at the level of the individual studies, 
and at the level of the combined dataset of both studies, the testing strategy  illustrated 
in Figure 12-1below will be implemented.
The hy potheses included in the test procedure are listed below:
Primary  endpoint (as described in Section 12.4 ):
H1(H'1): secukinumab [ADDRESS_37394] to 
HiSCR after 16 weeks of treatment.

[COMPANY_001] Confidential Page 83
Amended Protocol Version 02 (Clean ) Protocol No. CAIN457M2301
H2(H'2): secukinumab [ADDRESS_37395] to 
HiSCR after 16 weeks of treatment.
Secondary endpoints:
H3(H'3): secukinumab [ADDRESS_37396] to 
percentage change from baseline in AN count at Week 16 
H4(H'4): secukinumab [ADDRESS_37397] to 
percentage change from baseline in AN count at Week 16
H5(H'5): secukinumab [ADDRESS_37398] to flare 
over 16 weeks of treatment
H6(H'6): secukinumab [ADDRESS_37399] to flare 
over 16 weeks of treatment
H7: secukinumab 300mg q2w s.c. is not different to placebo regimen with respect to NRS30 
at Week 16
H8: secukinumab [ADDRESS_37400] to percentage change 
from baseline in AN count at Week 16 could be demonstrated if H3(H'3) and/or H4(H'4) is/are 
rejected and the treatment effect is in favor of Secukinumab. Efficacy  of two secukinumab 
regimens compared to placebo with respect to flare over 16 weeks could be demonstrated if 
H5(H'5) and/or H6(H'6) is/are rejected and the treatment effect is in favor of secukinumab. 
Efficacy  of two secukinumab regimens compared to placebo with respect to Pain/NSR30 at 
Week 16 could be demonstrated if H7and/or H8is/are rejected and the treatment effect is in 
favor of secukinumab.

[COMPANY_001] Confidential Page 84
Amended Protocol Version 02 (Clean ) Protocol No. CAIN457M2301
Figure 12-1 Testing strategy
Testing procedure and type-I-error control in the planned submission includes studies 
CAIN457M2301 and CAIN457M2302 (both with identical design). Hypotheses can only be 
tested in the order as indicated by [CONTACT_37296]. The hypothesis H1of the primary  objective 
(HiSCR at Week 16) for the high dose secukinumab regimen (q2w) versus placebo will be 
tested at 4α/5 while the hypothesis H2 of the primary  objective (HiSCR at Week 16) for the low 
dose secukinumab regimen (q4w) versus placebo will be tested at α/[ADDRESS_37401] 
one of H1 and/or H2 are/is rejected then H3 and/or H4 (percentage change from baseline in AN 
count at Week 16), is tested. If at least one of H3 and/or H4 are/is rejected, then the 
corresponding alpha will be passed to H5 and/or H6 (flare over 16 weeks) respectivel y. Once 
HiSCR , percentage change inAN count and flare hypotheses for a secukinumab regimen are 
rejected, the respective 4α/5 for the high dose and α/5 for the low dose can be passed on to the 
other regimen’s h ypotheses, if they  are not alread y rejected at the initial significance level (i. e., 
α/5 for the low dose and 4α/5 for the high dose). If both studies independently reject the primary 
null-hypothesis on the same secukinumab regimen (H1 and H'1, or H2 and H'2),then the 
corresponding secukinumab regimen’s pain h ypothesis ( H7or H8) can be tested. Additionally , 
the significance level for the pain h ypothesis can be passed from one dose regimen to the other
dose regimen if one pain dose regimen is rejected and the primary  null-hypothesis on the two 
secukinumab regimen are all rejected. The initial significance level for pain hypothesis (H7 
and/or H8) is set to α-α2. The subtraction of α2is to account for the maximum possible type I 
error to claim a success for HiSCR, percentage change in AN count and flare in both studies. 
Therefore, the type I error rate is controlled at level αfor the submission on all hypothesis 
endpoints. The detailed information regarding the significance level of H7and H8can be found 
in Section 16.3 (Appendix 3: Type I alpha for the pain hypothesis). Under the global null 
hypothesis (i.e. no difference between secukinumab and placebo), the testing procedure 
outlined above controls the t ype Ierror rate (one -sided) at the study -level to <0.025, and at the 
submission level to <0.000625(= 0.0252). Considering all possible configurations of true and 
false null hypotheses, the ty pe Ierror control at the level of the submission is <0.000625 for the 
primary  objectives, and <0.025 for all hy potheses ( Bretzet al 2019).

[COMPANY_001] Confidential Page 85
Amended Protocol Version 02 (Clean ) Protocol No. CAIN457M2301
12.5.2 Safety  endpoints
All safet y evaluations will be performed on the Safety set.
Adverse events
Treatment emergent AEs (events started after the first dose of study  treatment and within [ADDRESS_37402] dose) will be summarized. Only 
primary  paths within MedDRA will be considered for AE reporting.
AEs will be summarized by [CONTACT_1601], for each treatme nt group, the number and percentage 
of subjects having any AE, having an AE in each primary  system organ class and having each 
individual AE (preferred term). Summaries will also be presented for AEs by [CONTACT_11370] y and for 
study  treatment related AEs. If a subject reported more than one AE with the same preferred 
term, the AE with the greatest severit y will be presented. If a subject reported more than one 
AE within the same primary s ystem organ class, the subject will be counted only once with the 
greatest se verity at the s ystem organ class level, where applicable.
Confidence intervals for relative frequencies will be derived as well according to the score 
method including continuity  correction b y Newcombe ( Newcombe 1998 ).
Separate summaries will be provided for death, SAE, other significant AEs leading to 
discontinuation and AEs leading to stud y treatment discontinuation.
A graphical display  of relative frequencies within sy stem organ classes will be presented.
Vital signs
Analy sis of the vital sign measurements using summary statistics for the change from baseline 
for each post-baseline visit will be performed. These descriptive summaries will be presented 
by [CONTACT_37297]. Change from baseline will only  besummarized for subjects 
with both baseline and post -baseline values.
Clinical laboratory  evaluations
The summary  of laboratory  evaluations will be presented for two groups of laboratory  tests 
(hematology  and serum chemistry ). Descriptive summary  statistics for the change from baseline 
to each study  visit will be presented. These descriptive summaries will be presented by [CONTACT_37298], laboratory  test and treatment group. Change from baseline will only  be summarized for 
subjects with both baseline an d post baseline.
For each parameter, the maximum change from baseline within each study  treatment period 
will be anal yzed analogously .
In addition, shift tables will be provided for all parameters based on Common Toxicity  grade 
Criteria (CTC). For these shift tables, the normal laboratory  ranges will be used to evaluate 
whether a particular laboratory  test value was normal, low, or high relative to the baseline value. 
These summaries will be presented by [CONTACT_37299]. Shifts will be 
presented for most extreme values post- baseline.

[COMPANY_001] Confidential Page 86
Amended Protocol Version 02 (Clean ) Protocol No. CAIN457M2301
Immunogenicity
All immunogenicity  results will be listed by  [CONTACT_1570], subject and visit/time.
Resource utilization
Data relating to resource utilization will be used for the purpose of economic evaluat ion and 
will be carried out and reported as a separate activity .
12.5.[ADDRESS_37403] and Cmin will be determined. 
Descriptive summary  statistics will include mean (arithmetic and geometric), SD, and CV
(arithmetic and geometric), median, minimum and maximum. 
12.5.4 DNA
Exploratory  DNA studies are designed to investigate the association between genetic factors 
(genoty pes) and clinical assessments (phenot ypes) which are collected during the clinical trial. 
With out prior evidence of a strong association, a number of possible associations are evaluated 
with exploratory  analyses. A range of statistical tests are used for the analyses. Additional data, 
from other clinical trials, are often needed to confirm associat ions. Alternatively, if the number 
of subjects enrolled in the study  is too small to complete proper statistical analy ses, the data 
may be combined, as appropriate, with those from other studies to enlarge the dataset for 
analysis.
12.5.[ADDRESS_37404] and visit. Summary  statistics will 
be provided by [CONTACT_10659]. The number of values outside of the limit s of quantification 
will be reported in each table. 
Exploratory  biomarker assessments will be reported separately
12.5.6 PK/PD relationships
The effect of the secukinumab serum concentration on HiSCR and other endpoints will be 
investigated if appropriate. Clinically  important subject covariates, such as Hurley  stage, 
geographical region, use of antibiotic, baseline body weight, age and baseline AN count will be 
investigated.
12.5.7 Patient reported outcomes
Please refer to Section 12.6 for the analy sis method of Patient reported outcomes.
12.6 Analysis of exploratory  endpoints
For the exploratory  endpoints analy ses, the estimates of the differences between secukinumab 
groups versus placebo group and the corresponding p -values for pairwise comparisons will not 
be adjusted for multiple comparisons as no formal confirmatory  hypothesis tests are planned.

[COMPANY_001] Confidential Page 87
Amended Protocol Version 02 (Clean ) Protocol No. CAIN457M2301
Subpopulation A nalysis
The number and percentage of HiSCR responders in bio -naive patients will be presented by 
[CONTACT_37300] h treatment group. 
The number and percentage of HiSCR responders in patients with body  weight lower and higher 
than 90kg ( 90kg and ≥90kg) will be presented by [CONTACT_37301].
To allow for a pairwise comparison betwe en the two secukinumab regimens and placebo at 
Week 16 in bio -naive patients, HiSCR at Week 16 will also be analy zed in bio -naive patients 
using logistic regression with treatment group, geographic al region, Hurley  stage, baseline AN 
count, use of antibiotic, and baseline bod y weight as explanatory variables. Odds ratios will be 
computed for the comparison of secukinumab dose regimens versus placebo utilizing the 
logistic regression model fitted. In case of response rates of 0or of 100in one of the 
treatment groups, Fisher’s exact test will be applied. Risk difference and confidence intervals 
for risk difference will be provided.
The subgroup analysis of patients with body weight lower and higher than 90 kg ( 90kg and 
≥90kg) will be anal yzed analogously  to bio -naive patients. 
Modified Hidradenitis Suppurativa Score
Summary  statistics will be provided for absolute and percent change from baseline of modified 
Hidradenitis Suppurativa Score by [CONTACT_37302] .
To allow for a pairwise comparison between two secukinumab regimens and placebo until 
Week 16, modified Hidradenitis Suppurativa Score up to Week 16 will also be anal yzed using 
a MMRM with treatment group, the respective baseline value, Hurley  stage, use of antibiotic, 
geographical region, baseline body weight, visit, baseline mHSS*visit interaction, and treatment 
group*visit as covariates, with unstructured covariance matrix.
HS-Physician's Global A ssessment
HS-PGA responder will be analyzed using logistic regression with treatment group, Hurley 
stage, geographical region, use of antibiotic, baseline body weight, baseline HS-PGA as 
explanatory  variables. Odds ratios will be computed for comparisons of secukinumab dose 
regimens versus placebo utilizing the logistic regression model fitted. In c ase of response rates 
of 0% or of 100% in one of the treatment groups, Fisher’s exact test will be applied. Risk 
difference and confidence intervals for risk difference will be provided. Multiple imputation 
will be applied in case of missing data and detai l information will be specified in Statistical 
Analy sis Plan.
Dermatology  Life Quality  Index (DLQI)
The Dermatology  Life Quality  Index (DLQI) is a 10-item dermatology -specific HRQo L 
measure presented to each subject from the randomization up to the study  end. The instrument 
contains six functional scales (i.e. symptoms and feeling, daily activities, leisure, work and 
school, personal relationships, treatment). Each question is answered with the following  

[COMPANY_001] Confidential Page 88
Amended Protocol Version 02 (Clean ) Protocol No. CAIN457M2301
response: “not at all,” “a little,” “a lot,” or “very  much”. Seven scores will be derived from the 
DLQI: the total score of each of the six dimensions as well as the total score over all items. The 
higher the score, the more quality  of life is impaired. The DLQI total score will be calculated 
by [CONTACT_37303] a maximum of 30 and a minimum of 0.
DLQI responder: Decrease of ≥ 5.0 points on DLQI total score will be considered as 
responder and logistic regression will be utilized for anal ysis with treatment group, Hurley  
stage, geographical region, use of antibiotic, baseline body weight, baseline DLQI score as 
explanatory  varia bles. Odds ratios and will be computed for comparisons of secukinumab 
dose regimens versus placebo utilizing the logistic regression model fitted. In case of 
response rates of 0% or of 100% in one of the treatment groups, Fisher’s exact test will be 
applie d. Risk difference and confidence intervals for risk difference will be provided. 
Multiple imputation will be applied in case of missing data and detail information will be 
specified in Statistical Analy sis Plan.
Summary  statistics will be provided for absolute and percentage change from baseline of 
the total score of each of the six dimensions as well as the total score b y visit up to the end 
of study  for each treatment group.
To allow for a pairwise comparison between two secukinumab regimens and placebo until 
Week 16, DLQI score up to Week 16 will also be anal yzed using a MMRM with treatment 
group, the respective baseline value, Hurley  stage, use of antibiotic, geographical region, 
baseline bod ywei ght, visit, baseline DLQI*visit interaction, and treatment group*visit as 
covariates, with unstructured covariance matrix.
Work Productivity and A ctivity Impairment (WPA I)
Summary  statistics will be provided for absolute and percentage change from baseline of WPAI 
component scores b y visit up to end of study . 
EQ-5D-3L
The EQ-5D is a questionnaire with 5 questions (regarding mobility , self-care, usual activities, 
pain/discomfort, and anxiety /depression) each with three categories (no problem, moderate 
problem, severe problems) and a health state assessment from 0 (worst possible health state) to 
100 (best possible health state). The number and percentage of subjects in each of the three 
categories for each question will be presented b y visit up to the end of stud y for each treatment 
group. Summary  statistics will be shown for the health state assessment by [CONTACT_37304].
PGI (PGI- s and PGI -c)
The number and percentage of subjects in each categor y will be presented by [CONTACT_37304]. 
HS S ymptom Diary
Summary  statistics will be provided for absolute and percentage change from baseline of HS 
symptom component scores and the absolute HS sy mptom component score by  [CONTACT_37305] .

[COMPANY_001] Confidential Page 90
Amended Protocol Version 02 (Clean ) Protocol No. CAIN457M2301
patients was increased to approximately 541 (15% increase from the original population of 471 
patients).
12.8.1 Primary  endpoint(s)
HiSCR: Based on adalimumab phase III placebo -controlled studies (PI[INVESTIGATOR_15597] I and II, 
respectivel y, Kimball et al 2016 ), a placebo response rate of 30% is assumed. The original total 
sample size of 471 patients for this trial is sufficient to achieve 93% power for the demonstration 
of 20% difference of secukinumab 300 mg q2w over placebo based on the primary  endpoint 
(HiSCR) when assuming a secukinumab response rate to be 50%. In regards to the comparison 
of secukinumab 300 mg q4w to placebo, we achieve 83 power to show superiority .
12.8.2 Secondary  endpoint(s)
The power mentioned for the Secondary  endpoints is conditional on the successful rejection of 
the null hypothesis for the primar y endpoint (HiSCR), and the testing procedures are defined in 
Section 12.5.1 .
Percentage change in AN count: b ased on adalimumab phase III placebo -controlled studies 
(PI[INVESTIGATOR_15597] I and II, respectively  (Kimball et al 2016 ), it is assumed that the difference between 
secukinumab and placebo is at least 18 in favor of secukinumab when considering the mean 
percentage change from baseline in AN count at Week 16. Although it is planned to use a 
repeated measures model for the anal ysis, an approximate sample size can be based on a simple 
t-test. The original sample size of 471 patients is sufficient to achieve 92power in 
secukinumab 300 mg q2w vs. placebo and 81power in secukinumab [ADDRESS_37405] deviation of 46 . 
Flare: Based on adalimumab phase III placebo -controlled studies (PI[INVESTIGATOR_15597] I and II, 
respectivel y, Kimball et al 2016 ), a placebo rate of 35% is assumed. The original sample size 
of 471 patients is sufficient to achieve 98% power for the demonstration of 20% difference of 
secuk inumab 300 mg q2w over placebo based on the second endpoint when assuming 
secukinumab 300 mg q2w rate to be 15%. Assuming the same rate for secukinumab 300 mg 
q4w, the original sample size would be sufficient to achieve 92power in a comparison of 
secukinumab 300 mg q4w vs. placebo.
Pain: Based on adalimumab phase III placebo -controlled studies (PI[INVESTIGATOR_15597] I and II, 
respectivel y, Kimball et al 2016 ), a placebo rate of 23% is assumed. Assuming 80% patients 
are qualified to calculate Pain variable NRS30, the original total sample size of 942 patients 
across two studies is sufficient to achieve 85% power for the demonstration of 13% difference 
of secukinumab 300 mg q2w over placebo based on the second endpoint when assuming the
rate to be 36%. The original sample size is also sufficient to achieve 70 power to demonstrate 
superiority  of secukinumab 300 mg q4w over placebo based on the same assumptions in regards 
to the rates of secukinumab and placebo as above.

[COMPANY_001] Confidential Page 91
Amended Protocol Version 02 (Clean ) Protocol No. CAIN457M2301
13 Ethical consi derations and administrative procedures
13.1 Regulatory  and ethical compliance
This clinical study  was designed and shall be implemented, executed and reported in accordance 
with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable 
local regulations (including European Directive 2001/20/EC, US CFR 21), and with the ethical 
principles laid down in the Declaration of Helsinki.
13.2 Responsibilities of the investigator and IRB/IEC
Before initiating a trial, the investigator/instit ution must obtain approval/favorable opi[INVESTIGATOR_18548]/Independent Ethics Committee (I RB/IEC) for the trial protocol, 
written informed consent form, consent form updates, subject recruitment procedures (e.g., 
advertisements) and any other written information to be provided to subjects. Prior to study 
start, the investigator is required to sign a protocol signature [CONTACT_5389]/her agreement 
to conduct the study  in accordance with these documents and all of the instructions and 
procedures found in this protocol and to give access to all relevant data and records to [COMPANY_001] 
monitors, auditors, [COMPANY_001] /Quality  Assurance representatives, designated agents of [COMPANY_001], 
IRBs/IECs, and regulatory  authorities as required. If an inspection of the clinical site is 
requested by a regulatory authority , the investigator must inform [COMPANY_001] immediately  that this 
request has been made.
13.[ADDRESS_37406]. In addition, after study  completion (defined as last patient last visit) 
and finalization of the study report the results of this trial will be submitted for publication and 
posted in a publicly  accessible database of clinical trial results, such as the [COMPANY_001] clinical trial 
results website and all required Health Authority  websites (e.g. Clinicaltrials.gov, EudraCT 
etc.) .
For details on the [COMPANY_001] publication policy  including authorship criter ia, please refer to the 
[COMPANY_001] publication policy  training materials that were provided at the trial investigator 
meetings.
13.[ADDRESS_37407] Quality  Management System (QMS) that includes all activities 
involved in quality  assurance and qualit y control, to ensure compliance with written Standard 
Operating Procedures as well as applicable global/local GCP regulations and I CH Guidelines.
Audits of investigator sites, vendors, and [COMPANY_001] systems are performed by [CONTACT_6663], 
independent from those involved in conducting, monitoring or performing quality  control of the 
clinical trial. The clinical audit process uses a knowledge/risk based approach.
Audits are conducted to assess GCP compliance with global and loca l regulatory requirements, 
protocols and internal SOPs, and are performed according to written [COMPANY_001] processes

[COMPANY_001] Confidential Page 92
Amended Protocol Version 02 (Clean ) Protocol No. CAIN457M2301
[ADDRESS_37408] be 
considered a protocol amendment, and unless such an amendment is agreed upon by [CONTACT_5386]/IEC and Health Authorities, where required, it cannot be implemented.
14.[ADDRESS_37409] be approved by [CONTACT_5343], health authorities where required, and the IRB/IEC prior to 
implementation.
Only  amendments that are required forsubject safet y may be implemented immediately 
provided the health authorities are subsequently  notified by [CONTACT_37306]/IEC is notified.
Notwithstanding the need for approval of formal protocol amendments, the investigator is 
expected to take any immediate action required for the safety  of any subject included in this 
study , even if this action represents a deviation from the protocol. In such cases, [COMPANY_001] should 
be notified of this action and the IRB/IEC at the study  site should be informed according to 
local regulations.

[COMPANY_001] Confidential Page 93
Amended Protocol Version 02 (Clean ) Protocol No. CAIN457M2301
[ADDRESS_37410]
Alavi A (2016) Discussion: What Heals Hidradenitis Suppurativa: Surgery, 
Immunosuppression, or Both? Plast. Reconstr. Surg. p. 230S -1S.
Andersen RK, Jemec GBE (2017) Pathoph ysiology  of Hidradenitis Suppurativa. p. 19-26.
Bettoli V, Join -Lambert O, Nassif A (2016) Antibiotic Treatment of Hidradenitis Suppurativa. 
Dermatol Clin p. 81 -9.
Bretz F, Maurer W, Xi D. (201 9) Replicability , reproducibility  and multiplici ty in drug 
development. CHANCE . p.4-11.
Bruin G, Loesche C, Ny irady  J, et al (2017) Population Pharmacokinetic Modeling of 
Secukinumab in Patients With Moderate to Severe Psoriasis. J Clin Pharmacol p. [ADDRESS_37411] MG (2013) Ana lysis of longitudinal trials with protocol 
deviation: a framework for relevant, accessible assumptions, and inference via multiple 
imputation. J Biopharm Stat p. 1352-71.
Deckers IE, Kimball AB (2016) The Handicap of Hidradenitis Suppurativa. Dermatol Clin p. 
17-22.
Deckers IE, van der Zee HH, Prens EP (2014) Epi[INVESTIGATOR_37212]: 
Prevalence, Pathogenesis, and Factors Associated with the Development of HS. p. 54 -60.
Dessinioti C, Zisimou C, Tzanetakou V, et al (2016) Oral clindam ycin and rifampi[INVESTIGATOR_37213]: a prospective stud y and 1 -year follow -up. 
Clin. Exp. Dermatol. p. 852-857.
Dohert y SD, Van Voorhees A, Lebwohl MG, et al (2008) National Psoriasis Foundation 
consensus statement on screening for latent tuberculosis infection in patients with psoriasis 
treated with s ystemic and biologic agents. J. Am. Acad. Dermatol. p. 209- 17.
Fimmel S, Zouboulis CC (2010) Comorbidities of hidradenitis suppurativa (acne inversa). 
Dermatoendocrinol p. 9 -16.
Finlay AY, Khan GK (1994) Dermatology  Life Quality  Index (DLQI) --a simple practical 
measure for routine clinical use. Clin. Exp. Dermatol. p. 210-6.
Garcia -Montoy a and Marzo -Ortega (2018 )The role of secukinumab in the treatment of 
psoriatic arthritis and ankylo sing spondy litis. Ther Adv Musculoskel etDis.Sep 6 ;10(9):169-
180.
Garg A, Kirb y JS, Lavian J, et al (2017) Sex -and Age -Adjusted Population Analy sis of 
Prevalence Estimates for Hidradenitis Suppurativa in the [LOCATION_002]. JAMA Dermatol p. 
760-764.
Horvát h B, Janse IC, Blok JL , et al (2017) Hurley  Staging Refined: A Proposal by  [CONTACT_37307]. Acta Derm. Venereol. p. 412 -413.
Humira (adalimumab) EPAR.

[COMPANY_001] Confidential Page 94
Amended Protocol Version 02 (Clean ) Protocol No. CAIN457M2301
Janse I C, Deckers IE, van der Maten AD, et al (2017) Sexual health and qu ality of life are 
impaired in hidradenitis suppurativa: a multicentre cross -sectional study . Br. J. Dermatol. p. 
1042 -1047.
Jemec GB E(2012) Clinical practice. Hidradenitis suppurativa. N. Engl. J. Med. p. 158 -64.
Kelly  G, Hughes R, McGarry  T, et al (2015) Dysregulated cy tokine expression in lesional and 
nonlesional skin in hidradenitis suppurativa. Br. J. Dermatol. p. 1431 -9.
Kelly  G, Sweeney  CM, Tobin AM, et al (2014) Hidradenitis suppurativa: the role of immune 
dysregulation. Int. J. Dermatol. p. 1186 -96.
Kimball AB, Ganguli A, Fleischer A (2018) Reliability  of the hidradenitis suppurativa clinical 
response in the assessment of patients with hidradenitis suppurativa. J Eur Acad Dermatol 
Venereol .p. 2254 -6.
Kimball AB, Jemec GB E, Yang M, et al (2014) Asses sing the validit y, responsiveness and 
meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical 
endpoint for hidradenitis suppurativa treatment. Br. J. Dermatol. p. 1434 -42.
Kimball AB, Kerdel F, Adams D, et al (2012) Adalimumab for the treatment of moderate to 
severe Hidradenitis suppurativa: a parallel randomized trial. Ann. I ntern. Med. p. 846-55.
Kimball AB, Okun MM, Williams DA, et al (2016) Two Phase 3 Trials of Adalimumab for 
Hidradenitis Suppurativa. N. Engl. J. Med. p. 422-34.
Lima AL, Karl I, Giner T, et al (2016) Keratinocytes and neutrophils are important sources of 
proinflammatory  molecules in hidradenitis suppurativa. Br. J. Dermatol. p. 514 -21.
Lipsker D, Severac F, Frey sz M, et al (2016) The ABC of Hidrad enitis Suppurativa: A 
Validated Glossary  on how to Name [CONTACT_37310]. Dermatology  (Basel) p. 137 -42.
Manuel O, Kumar D (2008) QuantiFERON -TB Gold assay  for the diagnosis of latent 
tuberculosis infection. Expert Rev. Mol. Diagn. p. 247 -56.
Matusiak Ł, Szczęch J, Bieniek A, et al (2016) Increased interleukin (IL) -17 serum levels in 
patients with hidradenitis suppurativa: I mplications for treatment with anti- IL-17 agents. J. 
Am. Acad. Dermatol. p. 670 -675.
Newcombe RG (1998) Two- sided confidence intervals for the s ingle proportion: comparison 
of seven methods. Stat Med p. 857 -72.
Pandey  K, Sekhri R, Sekhri V (2018) IL -17 inhibitor Secukinumab in refractory  Hidradenitis 
Suppurativa: A case report.
Revuz J (2009) Hidradenitis Suppurativa J Eur Acad Dermatol Venereol. Sep23;(9):985-98.
Sartorius K, Emtestam L , Jemec GB E, et al (2009) Objective scoring of hidradenitis 
suppurativa reflecting the role of tobacco smoking and obesity . Br. J. Dermatol. p. 831 -9.
Schuch A, Fischer T, Boehner A, et al (2018) Successful Treatment of Severe Recalcitrant 
Hidradenitis Suppurativa with the I nterleukin -17A Antibody  Secukinumab. Acta Derm. 
Venereol. p. 151 -152.

[COMPANY_001] Confidential Page 95
Amended Protocol Version 02 (Clean ) Protocol No. CAIN457M2301
Storer MA, Danesh MJ, Sandhu ME, et al (2018) An assessment of the relative impact of 
hidradenitis suppurativa, psoriasis, and obesity  on quality  of life. Int. J. Women's 
Dermatology  4; 198–202.
Thorlacius L, Ingram JR, Villumsen B, et al (2018) A Core Domain Set For Hidradenitis 
Suppurativa Trial Outcomes: An I nternational Delphi Process. Br. J. Dermatol.
Thorlacius L, Theut Riis P, Jemec GBE (2017) Severe hidradenitis suppurativa responding to 
treatment with secukinumab: a case report. Br. J. Dermatol.
Wolk K, Warszawska K, Hoeflich C, et al (2011) Deficiency  of IL -22 contributes to a chronic 
inflammatory  disease: pathogenetic me chanisms in acne inversa. J. I mmunol. p. 1228 -39.
Zouboulis CC, Desai N, Emtestam L , et al (2015) European S1 guideline for the treatment of 
hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol p. 619 -44.
Zouboulis CC, Tzellos T, Ky rgidis A, et al (2017) Development and validation of the 
International Hidradenitis Suppurativa Severity  Score S ystem (IHS4), a novel dy namic 
scoring s ystem to assess HS severity . Br. J. Dermatol. p. 1401 -1409.

[COMPANY_001] Confidential Page 96
Amended Protocol Version 02 (Clean ) Protocol No. CAIN457M2301
16 Appendices
16.1 Appendix 1: Clinically  notable laboratory  values and vital signs
The following criteria will be used to define expanded limits and notable abnormalities of key 
laboratory  tests.
No specific action is pre-defined within this protocol to respond to specific abnormal laboratory 
values, as it will be decided by [CONTACT_37308] y abnormal values, taking into account the overall status of the subject.
Liver Function and Related Variables
Alanine transaminase (ALT) (SGPT): > 3 x Upper L imit of Normal (ULN)
Aspartate transaminase (AST) (SGOT): > [ADDRESS_37412]
Total bilirubin: > [ADDRESS_37413]
Alkaline phosphatase (ALP) : > 2.[ADDRESS_37414]
Renal Function
Creatinine (serum): > 1.[ADDRESS_37415]
Hematology
Hemoglobin: ≥ 2g/dl decrease from baseline
Platelet count: < Lower Limit of Normal (LLN)
White blood cell count: < 0.[ADDRESS_37416]
Neutrophils: < 0.[ADDRESS_37417]
Eosinophils: > 1.[ADDRESS_37418]
Lym phocy tes: > 1.[ADDRESS_37419]
Urinaly sis
Protein urine dipstick: ++*
* ++ is ≥ 100 mg/dl

[COMPANY_001] Confidential Page 97
Amended Protocol Version 02 (Clean) Protocol No. CAIN457M2301
16.2 Appendix 2: Blood samples collection
Table 16-1 Blood log: Time schedule for blood sampling
Period Visit NameHematologyClinical 
ChemistrySerum 
pregnancy  
testBlood sample for 
PKBlood 
sample for 
IG Biomarker TB testTotal 
volume 
(ml) Volume (ml)Volume 
(ml) Volume (ml)Dose 
Ref. ID#Volume 
(ml)Volume 
(ml)Volume 
(ml)Volume 
(ml)
Screening Screening 1 4.8 3.5 2 4 14.3
Screening 2 0
Treatment Period 1 Baseline 4.8 5 1 2 2 15 28.8*
Week 1 0
Week 2 4.8 3.5 8.3
Week 3 0
Week 4 4.8 3.5 8.3
Week 8 4.8 3.5 8.3
Week 12 4.8 3.5 8.3
Week 16 /EOT1 4.8 5 2 2 2 15 28.8
Treatment Period 2 Week 17 0
Week 18 4.8 3.5 8.3
Week 19 0
Week 20 4.8 3.5 8.3
Week 24 3 2 2
Week 28 4.8 3.5 8.3
Week 32 0
Week 36 0
Week 40 0
Week 44 4.8 3.5 8.3
Week 48 0
Week 52/EOT2 4.8 5 4 2 2 15 4 32.8

[COMPANY_001] Confidential Page 98
Amended Protocol Version 02 (Clean) Protocol No. CAIN457M2301
Period Visit NameHematologyClinical 
ChemistrySerum 
pregnancy  
testBlood sample for 
PKBlood 
sample for 
IG Biomarker TB testTotal 
volume 
(ml) Volume (ml)Volume 
(ml) Volume (ml)Dose 
Ref. ID#Volume 
(ml)Volume 
(ml)Volume 
(ml)Volume 
(ml)
Post-Treatment Follow -Up Week 60 4.8 3.5 4 2 2 12.3
* For patients who sign optional DNA sampling ICF, 3 ml of blood will be additionally collected at baseline visit. # Dose reference IDs 1, 2 and 3 are 
collected pre -dose; scheduled post- dose time points for dose reference ID [ADDRESS_37420] study dose.

[COMPANY_001] Confidential Page 99
Amended Protocol Version 02 (Clean) Protocol No. CAIN457M2301
16.3 Appendix 3: Ty pe I alpha for the pain hy pothesis
Pain will be analy zed based on pooled data.Detailed information are listed in below table:
Table 16-2 Type I alpha for the pain hy pothesis
ScenarioHypothesis rejected within two studies Alpha for pooled pain
300q2
w
HiSCR300q2 w
AN 
count300q2
w
Flare300q4w
HiSCR300q4w
AN 
count300q4w
Flare300q2w
Pooled
Pain300q4w
Pooled 
Pain
H1, H'1H3, H'3 H5, H'5H2, H' 2 H4,H'4 H6, H'6 H7 H8
1 Y N N N N N 4α/5 -α2-
2 Y Y N N N N 4α/5 -α2-
3 Y Y Y N N N 4α/5 -α2-
4 N N N Y N N - α/5 -α2
5 N N N Y Y N - α/5 -α2
6 N N N Y Y Y - α/5 -α2
7 Y N N Y N N 4α/5 -α2α/5-α2
8 Y Y N Y N N 4α/5 -α2α/5-α2
9 Y Y Y Y N N 4α/5 -α2α/5-α2
10 Y N N Y Y N 4α/5 -α2α/5-α2
11 Y Y N Y Y N 4α/5 -α2α/5-α2
12 Y Y Y Y Y N 4α/5 -α2α/5-α2
13 Y N N Y Y Y 4α/5 -α2α/5-α2
14 Y Y N Y Y Y 4α/5 -α2α/5-α2
15 Y Y Y Y Y Y 4α/5 α/5
For scenario 1,2 and 3, where H1, H'1 are rejected, and H2, H'2 are not rejected, then H7 could 
be tested at level 4 α/5-α2, and H8 cannot be tested.
For scenario 4, 5 and 6, where H2, H'2 are rejected, and H1, H'1 are not rejected, then H8 could 
be tested at level α/5-α2, and H7 cannot be tested.
For scenario 7 to 14, where H1, H'1, H2, H'[ADDRESS_37421] one of the hypothesis H3, 
H'3, H4, H'4, H5, H'5 , H6, H'6 are not rejected, then H7 and H8 could be tested. Initially , H7 
is tested at level 4 α/5-α2 and H8 is tested at level α/5-α2. If H7 (H8) is rejected, H8 (H7) can be 
tested at level α-2α2.
For scenario 15 where H1, H'1, H2, H'2, H3, H'3, H4, H'4, H5, H5’, H6, H6’ are all rejected, 
then H7and H8 could be tested at level α. Initially, H7 is tested at level 4α/5and H8 is tested 
at level α/5. If H7 (H8) is rejected, H8 (H7) can be tested at level α.
The subtraction of α2would be subtracted in the initial significance level for pain hypothesis 
(H7 and/or H8) is to account for the maximum possible type I error to claim a success for 
HiSCR, AN count and/or Flare in both studies. Therefore, the type I error rate is controlled at 
level αfor the submission on all hypothesis endpoints. Under the global null hypothesis (i.e. no 
difference between secukinumab and placebo), the testing procedure outlined above controls 

[COMPANY_001] Confidential Page 100
Amended Protocol Version 02 (Clean) Protocol No. CAIN457M2301
the type I error rate (one-sided) at the study -level to 0.025, and at the submission level to 
0.000625( 0.0252). Considering all possible configurations of true and false null hy potheses, 
the type I error control at the level of the submission is 0.000625 for the primary  objectives, 
and 0.025 for all h ypotheses ( Bretz et al 2019).
